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Introduction: Caesarean section births are the most important known common factor that has 
been linked with post-partum bacterial infections. According to the current Standard Treatment 
Guidelines, the prophylactic dose in surgical prophylaxis is a single dose of cefazolin, equal to 
the standard therapeutic dose, and given as a single stat dose prior to surgery. Multiple-dose 
regimes are associated with higher costs compared to a single-dose regime, not just in terms of 
acquisition costs but also in terms of staff time. 
Aim: To contribute to the rational use of antibiotics, through the application of a medicines use 
evaluation in a district hospital. 
Methods: A retrospective Medicine Use Evaluation (MUE) was carried out at Heidelberg 
Hospital in Gauteng. The quantitative data was collected over a 3 month study period in which 
the medical records of 120 female patients who delivered through Caesarean section was 
captured using the Medicine Use Evaluation data sheet. The qualitative phase involved 
structured interviews with medical officers to establish reasons for non-compliance. A total 
of 7 medical officers participated in the interviews. 
Results: None of the 120 patients received the stipulated regimen as recommended in The 
Standard Treatment Guidelines. Patients either received: 1 day of cefazolin, administered every 
8 hours intravenously (83/120, 69.2%) or 3 days’ of cefazolin administered every 8 hours 
(37/120, 30.8%). Every HIV-uninfected woman (83/120, 69.2%) received 3 doses of cefazolin, 
whereas every HIV-infected woman received 9 doses of cefazolin and metronidazole 
intravenously. All patients also received 5 days’ of oral antibiotics on discharge. Eighty-five 
percent of patients did not have a justifiable reason for receiving a full therapeutic course. 
Discussion: Clear evidence was provided that the administration of antibiotic prophylaxis 
for Caesarean section deliveries at Heidelberg Hospital was irrational. Using MUE methods, 
the study identified different elements of non-compliance with the national 
recommendations. The study did not provide any justifications for the therapeutic use of 
antibiotics in patients without established or suspected infections post-operatively. 
Recommendations: The Standard Treatment Guidelines should provide unambiguous 
recommendations for the use of prophylaxis in women undergoing Caesarean sections 
in addition to the management of women suspected of having an established infection, 
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CHAPTER I: INTRODUCTION 
This chapter provides the overall context for the study, locates it within the overall health 
system and the theoretical background, and then lists the aim and specific objectives. 
1.1 Health and healthcare delivery in South Africa 
The health system in South Africa is comprised of the public health sector, which is funded by 
the state and serves approximately 83% of the population, and the private for-profit sector, 
which is better resourced, usually funded by the subscriptions of individuals to medical aid 
schemes and serves approximately 17% of the population (Council for Medical Schemes 
Annual Report, 2015). Public health utilised an estimated 15% of the government's total budget 
in 2015, most of which was allocated to the nine provincial departments via the equitable share 
mechanism (Day and Gray, 2016). The total expenditure on health as a percentage of the Gross 
Domestic Product (GDP) in 2015 was 8.5%, with almost half each expended in the public and 
private sectors, respectively (Day and Gray, 2016). Given the levels of impoverishment and 
unemployment in South Africa, the greater burden of healthcare (if not expenditure) continues 
to remain the responsibility of the Department of Health, provided mainly through the public 
sector.  
 
Due to the burden of disease in South Africa, the treatment and prevention of human 
immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS) 
and tuberculosis (TB) consumes a large proportion of national expenditure. More than 70% of 
all persons living with HIV in the world are in sub-Saharan Africa, with 6.19 million South 
Africans (11.2% of the population) living with HIV (Jobson, 2015). The national antenatal HIV 
prevalence in South Africa was 29.7% in 2015, with the highest prevalence (42.5%) in pregnant 
women aged 30-39 years (South African National Department of Health, 2015). In 2015, 
Statistics South Africa estimated that 531 965 people died, with 30.5% of these deaths being 
AIDS-related (Statistics South Africa, 2015). This can impact negatively on the country if 
economically active people are dying, thus leaving their children to fend for themselves. In 
2015, R15.9 billion from the health budget was utilised for HIV treatment and prevention and 
R740 million for the treatment of tuberculosis, including enhanced screening and earlier 




The public sector faces considerable human resource constraints (Jobson, 2015). Positive 
accomplishments of the past decade are largely overshadowed by the burden of AIDS on 
mortality and the health system. Certainly, the management of the HIV and AIDS epidemic will 
continue to dominate the next decade and beyond. Efforts to sustain financing for the prevention 
and treatment of HIV and AIDS, while improving service efficiency and quality of care, will 
require new funding formulas such as those envisaged in a National Health Insurance system 
(Minister of Health, 2015). However, despite the extent of the challenge there are opportunities 
for considerable systems improvements and advancement in relation to the major policy 
priorities (Harrison, 2009). 
 
1.1.1 The public healthcare system 
Care is delivered through different levels in the public healthcare system in South Africa. The 
basis of the public health system is the primary healthcare clinics, which are the first line of 
access for patients requiring healthcare services at no cost. Accessibility of primary healthcare 
facilities has improved over the years, although there are some reports that the quality of service 
provided has declined. District hospitals are generally the next level of healthcare. Patients are 
referred to the district hospitals from primary healthcare clinics when they require more 
sophisticated treatment. More sophisticated care available at district hospitals is provided 
through regional hospitals. The tertiary level includes the central or academic hospitals, where 
even more specialised treatment and advanced diagnostic procedures are available. These 
academic hospitals also serve as training institutions for healthcare providers (Jobson, 2015). 
Lastly, there are specialised hospitals, such as those providing psychiatric and tuberculosis 
services. According to Jobson (2015), there were 4200 public health facilities in South Africa in 
2015, with each clinic providing on average for 13 718 persons (a figure that exceeds the WHO 
guidelines of 10 000 per clinic). Jobson also noted that the public-sector dependent population 
averaged 2.5 visits per year to public health facilities and that bed occupancy rates in public 
sector hospitals were between 65% and 77%. Since 1994, more than 1600 clinics have been 
built or upgraded. For 2.5 million South Africans, their nearest clinic is more than 5 kilometres 
away from their homes.  
 
There were 376 public hospitals in the country in 2015, of which 143 were in urban areas and 
233 in rural areas (Jobson, 2015). In 2015, R31.9 billion of the health budget was utilised for 
primary healthcare services and R88.2 billion for hospital care (Day and Gray, 2016). Sixty-four 
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percent of public hospitals were district hospitals, with regional and specialised hospitals 
making up 16% each of the total number. Together academic and central hospitals made up less 
than 4% of all hospitals in the public sector (Jobson, 2015). For most South Africans, in 
particular those in rural areas, district hospitals are the only hospitals to which they would most 
likely get admitted. A district hospital has a 24-hour emergency service and an operating 
theatre. This is the first level of referral and generalist staff (ordinary medical officers, as 
opposed to medical specialists) are available with access to basic diagnostic and therapeutic 
services, such as basic radiography and basic laboratory tests. A functional operating theatre 
would be present in which operations are performed regularly under general anaesthesia 
(although there would be no specialist anaesthesiologist available). However, there would be no 
intensive care unit. According to the World Health Organization’s (WHO) functional definition, 
district hospitals should provide diagnostic, treatment, care, counselling and rehabilitation 
services. They should cover the following clinical disciplines at generalist level: family 
medicine and primary healthcare, internal medicine, obstetrics, psychiatry, rehabilitation, 
surgery, paediatrics and geriatrics (Cullinan, 2006). 
1.1.2 The private healthcare system 
The private healthcare system on the other hand provides services on a for-profit basis, mostly 
by self-employed health professionals. These services are usually funded by the subscriptions of 
individuals to medical aid schemes, supplemented by employer contributions. There were 238 
private hospitals in the country in 2015, of which 188 were in urban areas and 50 in rural areas 
(Jobson, 2015). The private healthcare sector covered approximately 17% of the population in 
2015. The medical aid schemes covered the needs of just over 8.8 million beneficiaries and 
received R140.2 billion worth of contributions (Council for Medical Schemes Annual Report, 
2015; Day and Gray, 2016). 
 
1.2 From the Millennium Development Goals to the era of Sustainable Development Goals 
In September 2015, the UN General Assembly adopted “Transforming our World: The 2030 
Agenda for Sustainable Development”, a plan outlining a new framework to replace the 
Millennium Development Goal (MDG) structure with the new Sustainable Development Goals 
(SDGs) (United Nations, 2015a). The SDGs comprise of 17 universal goals, with 169 targets 
and 230 indicators leading up to 2030. These goals are intended to build on the momentum and 
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enthusiasm generated by the MDGs, but also to reframe them within the context of a broader 
range of environmental and societal challenges (Griggs et al., 2013). The Global Strategy for 
Women’s, Children’s, and Adolescents’ Health 2016–2030 has aimed to highlight the global 
discussion of maternal mortality, with a variety of programmes which are aimed at improving 
the health of women and children (WHO, 2016a). Health is a core dimension of the SDGs, with 
SDG 3 aiming to “ensure healthy lives and promote well being for all at all ages”. 
 
As the MDG era has now reached its end and the SDG era is commencing, it is worth reflecting 
on the degree of global, regional, and national progress toward MDG 5, the specific MDG that 
targeted maternal health. Whereas MDG 5 set a target of reducing the maternal mortality ratio 
(MMR; defined as the number of maternal deaths per 100 000 livebirths) by 75% between 1990 
and 2015, SDG 3.1 sets a specific target for all countries to lower MMR to less than 70 by 2030 
(GBD 2015 Maternal Mortality Collaborators, 2016). In 2015, an estimated 303 000 global 
maternal deaths occurred, representing a 44% reduction from 1990. Sub-Saharan Africa had the 
most maternal deaths, accounting for 201 000 (66%) maternal deaths globally, with southern 
Asia accounting for 66 000 (22%) maternal deaths. The African share has seen a drastic increase 
from 42% in 1990 to 66% in 2015. While maternal mortality has declined globally, South 
Africa was one of the three countries which showed an increased MMR, with 6.4% of maternal 
deaths suspected to be HIV-related. The impact of high fertility rates, poor maternal health 
systems, and low perinatal survival are apparent (Graham et al., 2016). In South Africa, the 
number of maternal deaths increased from 1558 to 1754 between 1990 and 2015 and the 
maternal mortality ratio increased from 153.8 to 157.9 per 100 000 livebirths between 1990 and 
2015 (GBD 2015 Maternal Mortality Collaborators, 2016). The GBD project has predicted that 
“as immediate mortality continues to decrease as a result of improved antenatal, obstetric, and 
post-partum care, it is therefore increasingly likely that the proportion of late maternal deaths 
will continue to increase” (GBD 2015 Maternal Mortality Collaborators, 2016). In 2015, 61.2% 
of 188 countries had already achieved the SDG target for MMR (GBD 2015 SDG 
Collaborators, 2016). 
 
The quantitative effect of MDG 5 is difficult to measure, but it is clear that it united the 
international community in striving to decrease maternal mortality. With the endorsement of 
SDG 3.1 and SDG 3.7, and better quality data, health systems will need to make informed 
decisions about how to prioritise actions needed to bring about further improvement. The steps 
that have been suggested include making changes to the cause of death data collection systems 
and the dissemination of data together with more effective and extensive action and policies to 
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promote young girls and women having accessible education, making comprehensive family 
planning services available, and ensuring that different types of reproductive care are made 
accessible to each and every woman for them to survive (GBD 2015 SDG Collaborators, 2016). 
In order to achieve the reproductive healthcare targets outlined in SDG 3.7.5, the international 
community will have to pay attention to the intricately related issues of “immigration, armed 
conflicts, epidemics and pandemics, environment, economic instability, and gender equality”, 
all of which can have considerable effects on the availability and quality of reproductive health 
services and the willingness of women to seek them (GBD 2015 SDG Collaborators, 2016). As 
much as there is global progress with regard to reducing maternal mortality, which has been 
accelerating in the past 15 years, a substantial amount of work is still left to complete. As 
explained by the GBD 2015 SDG Collaborators (2016): “more than 250 000 women died during 
or following pregnancy in 2015, most of which were preventable deaths”. In South Africa the 
total number of maternal deaths increased from 1249 in 2010 to 1270 in 2014 (Day and Gray, 
2016). 
 
Some of the issues that need to be flagged as priorities are the poor skills of healthcare 
providers, low facility capability in terms of diagnostic tools and equipment, and inadequate 
lengths of stay. In a study by Campbell et al. (2016), the authors reported that most of the 
studied facilities in sub-Saharan Africa were badly equipped to provide emergency obstetric 
care services, in particular facilities at lower levels of the health system. There is a substantial 
room for improvement to provide respectful care of high quality in order to ultimately improve 
patient and healthcare provider satisfaction (Campbell et al., 2016). 
 
1.3 Antimicrobial stewardship programmes and management of resistant organisms  
The development of antimicrobials has been described as “one of the great landmarks of modern 
medicine” (Domínguez et al., 2016). Although this has enabled a significant reduction in 
morbidity and mortality associated with microbial infections, it has also created a vicious cycle, 
in which the indiscriminate and inappropriate use of antimicrobials in both humans and animals 
has become associated with increased costs for treatments, risks of unwanted side effects and, 
more importantly, the emergence of antimicrobial resistance (Domínguez et al., 2016). 
Antimicrobial resistance (AMR) is an emerging public health threat which has managed to draw 
the attention of national and international organisations. The World Health Organization has 
defined the emergence of AMR as an increasingly serious threat to global public health that 
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requires action across all government sectors and society (WHO, 2015). There are several 
factors that have contributed to the spread of AMR in many communities. One contributing 
factor in particular, that has been frequently discussed, is the misuse or overuse of antibiotics in 
human medicine (Laxminarayan et al., 2013). Existing estimates show that between 25%–50% 
of hospitalised patients receive antibiotics, with between 30% and 50% of antibiotic use being 
considered to be inappropriate (Dellit et al., 2007). Published literature reveals a direct link 
between antibiotic use and the development of resistance (Goossens et al., 2005; Aldeyab et al., 
2012; Livermore et al., 2013). 
A recent World Health Organization report on surveillance of resistance to antibacterial agents 
in bacteria commonly associated with hospital and community infections has revealed increased 
resistance and/or decreased susceptibilities (WHO, 2014). It was reported that the resistance of 
Escherichia coli to third-generation cephalosporins and fluoroquinolones and that of 
Staphylococcocus aureus to methicillin was 50% or more in five out of the six WHO regions. 
Klebsiella pneumoniae resistance to third-generation cephalosporins was reported to be greater 
than 50% in all six WHO regions. Carbapenem-resistant K. pneumoniae was reported in all 
WHO regions, with reports in two regions exceeding 50%. It was further reported that the non-
susceptibility of Streptococcus pneumoniae to penicillin was more than 50% in all six WHO 
regions (WHO, 2014; Akpan et al., 2016). A similar AMR surveillance report from England 
revealed increased resistance of E. coli and K. pneumoniae to ciprofloxacin, third-generation 
cephalosporins, gentamicin, and both imipenem and meropenem (Akpan et al., 2016). The same 
report, however, indicated decreased resistance of Pseudomonas aeruginosa to ceftazidime, 
gentamicin, and imipenem/meropenem. Recent reports stress that patients who have been 
infected by antibiotic-resistant bacteria have a two-fold increase in mortality as opposed to those 
infected with sensitive bacteria (Akpan et al., 2016). 
As a result of the lack of investment in research and development and the dearth of new 
antibacterials, a bleak future for the treatment of infections caused by multi-resistant bacteria 
has been predicted (Domínguez et al., 2016). The progressive contraction in the number of 
available alternative antimicrobials has led to the "re-discovery" of older antimicrobials whose 
use had virtually been abandoned for various reasons, including toxicity. In this regard, colistin 
provides a prominent recent example. It is therefore of utmost importance that monitoring of 
antimicrobial consumption, both in the community and in the hospital setting, coupled with 
continuing education about the proper use of these scarce resources, is practised at all times 
(Domínguez et al., 2016). Monitoring the consumption of antimicrobials in hospitals is 
particularly important, both to evaluate the factors that determine antimicrobial consumption as 
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well as to evaluate the impact of substituting antibiotics in cases of shortage, which might also 
influence the development of bacterial resistance (Domínguez et al., 2016).  
Antimicrobial stewardship programmes (ASPs) are intended to address all of the contributory 
factors to misuse and overuse of antibiotics (Johannsson et al., 2011). Many hospital 
programmes may adopt restrictive measures as well as persuasive interventions such as audit 
and feedback methods (Davey et al., 2013). Extensive surveillance of antimicrobial 
consumption thus forms a core part in many ASPs. The methods used may vary in different 
institutions but the outcome of reducing the emergence of resistance remains common. It has 
been claimed that there is no conclusive evidence that a decline in antibiotic use necessarily 
results in reduced antimicrobial resistance (Holmes et al., 2016). Certainly, it is imperative to 
monitor patient outcomes when embarking on ASPs in order to ensure that individual patients’ 
health is not harmed through either restrictive or persuasive policies. 
Lanbeck et al. (2016) have highlighted that it is vital to analyse the economic consequences of 
ASPs, to make sure that decisions to introduce ASPs can be objectively compared with other 
potential efforts. Hence the implementation and operational costs need to be considered. The 
full health-economic consequences of ASPs are complex to calculate due to uncertainties about 
long-term effects on costs and benefits, as well as due to uncertainties in attributable costs and 
effects of the infection, which most commonly increase the length of stay in the hospital 
(Lanbeck et al., 2016).  
ASPs function best when they are motivated by quality considerations and are focused on 
improving the use of antibiotics in healthcare institutions. An ASP is essentially a programme 
aimed at optimising clinical outcomes and minimising unintended consequences (Dellit et al., 
2007). Proposed strategies to achieve these goals have included prospective audit with 
intervention and feedback, formulary restriction and pre-authorisation, education, guidelines and 
clinical pathways, antimicrobial cycling and scheduled antimicrobial switch programmes, 
specific antimicrobial order forms, automatic stop orders, recommending combination therapy, 
streamlining or de-escalation of therapy, dose optimisation, conversion from parenteral to oral 
therapy (IV to oral switch), computer surveillance and the provision of decision support 
(Owens, 2008). A multidisciplinary team approach is required for an effective ASP, bearing the 
main responsibility for promoting prudent antimicrobial use. As recommended by the Infectious 
Diseases Society of America and the Society for Healthcare Epidemiology of America 
(IDSA/SHEA) ASP guidelines, this multidisciplinary team should consist of a medical 
practitioner and a clinical pharmacist with adequate infectious diseases training as core 
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members (Dellit et al., 2007). The inclusion of a clinical microbiologist, information system 
specialist, infection control specialist, hospital epidemiologist, and hospital administrator is 
considered optimal. Healthcare organisations are also encouraged to develop quality measures 
or indicators to monitor and evaluate the impact of their ASPs (Akpan et al., 2016). 
According to a review by Smaill and Hofmeyr (2002), in women undergoing Caesarean 
sections, there is evidence to suggest the alteration of the cervicovaginal flora, regardless of the 
use of antibiotics. However in the past this did not cause a problem with managing resistant 
organisms (Galask, 1987). The development of antibiotic resistance may now be a factor with 
the widespread use of antimicrobial prophylaxis (Shlaes et al., 1997). There are no data to 
support the contention that correct use of a short course of antimicrobial prophylaxis will cause 
significant bacterial resistance nor evidence that a policy of strictly enforced and restricted 
antibiotic prophylaxis for CS has harmful effects that outweigh its benefits, even in those 
women perceived to be at low risk. One of the recommendations to avoid antimicrobial 
resistance is to place emphasis on optimising the choice and the duration of prophylactic 
antibiotics (Shlaes et al., 1997). Careful monitoring of trends in antibiotic resistance should be 
used to establish appropriate practice guidelines and to monitor the impact of institutional 
policies. Susceptibility testing of significant bacterial isolates should be used as a guide for 
treatment in women who develop infection, despite the provision of appropriate prophylaxis 
(Smaill and Hofmeyr, 2002). 
 
1.4 Caesarean section as a means of delivery  
Caesarean section (CS) was introduced into obstetric practice as a life saving procedure both for 
the mother and the baby. As with other procedures of similar complexity, “its use follows the 
healthcare inequity pattern of the world: underuse in low income settings, and adequate or even 
unnecessary use in middle and high income settings” (WHO, 2010). Numerous studies have 
shown an inverse relationship at population level between CS rates and maternal and infant 
mortality in low-income countries where most sectors of the population do not have access to 
basic obstetric care (Betrán et al., 2007, Althabe et al., 2006, Ronsmans et al., 2006). However, 
other studies have shown that there is no additional benefit for both the mother and baby if CS 
rates are above a certain limit, and high CS rates could result in negative consequences in both 
maternal and child health when indicated inappropriately, as the potential harm may exceed the 
potential benefit of the CS (WHO, 2010). 
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Obstetric factors occurring around birth were reported to be the main reasons leading to CS 
delivery. In a study by Abebe et al. (2016), the major obstetric indications for women who 
delivered by CS were obstructed labour (30.7%), foetal distress (15.9%) and abnormal 
presentation (13.4%). However with the currently available option of elective CS, rates of CS 
have steadily increased in most middle- and high-income countries without medical 
justification. According to the Guidelines for Maternity Care in South Africa (2016) the 
indications stated for elective CS delivery were triplets (or higher order pregnancy), intrauterine 
growth restriction, first twin breech or transverse lie after 37 weeks, or previous Caesarean 
section. Maternal request is one of the frequent factors contributing to the trend towards higher 
CS rates, resulting in obstetricians facing high demands for non-medically indicated CS 
(Department of Health, 2016).  
 
In general, the inability of health services to offer necessary CS in non-urban and under-
resourced settings is a growing problem globally. However, sharp increases in CS rates in 
some developing countries, especially in Latin America, have become a major problem. Data 
available for Brazil show that the overall rate of CS for that country is 30%, reaching as high 
as 50% in certain provinces (Barros et al., 1991, Faundes and Cecatti, 2005). In this 
situation, other factors including malnutrition and poor social conditions are likely to 
exacerbate the already higher risk of infectious morbidity and mortality associated with CS. 
Another serious concern is the fact that a considerable number of CS are unnecessary and are 
planned in advance, with the additional potential risk of iatrogenic prematurity (Cecatti, 
2005). 
 
In 1985, the WHO stated that there is no justification for any region to have CS rates higher 
than 10-15% (WHO, 1985). The WHO assessed the prevalent CS rates in 2008 in 137/192 
United Nations member states, representing 95% of global births (WHO, 2010; UNICEF, 2008) 
and reported that approximately 18.5 million CS were performed globally each year, with 
approximately 40% of countries having CS rates <10%, about 10% having CS rates between 10 
and 15%, and approximately 50% having CS rates >15%. With regard to the 15% target, an 
estimated 6.2 million CS were performed in excess of this target per annum. China and Brazil 
accounted for almost 50% of the total number of unnecessary CS (WHO, 2010). The WHO 
further stated that, from a population-based approach, the indications for the excess number of 
CS were not likely to be medically warranted. The 15% upper limit suggested by WHO in 1985 
has however been challenged. For example, in high-income countries, older women delivering 
for the first time and babies with increased birth weight may require more CS. However, the 
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WHO nevertheless highlighted that current studies have demonstrated thus far that there is no 
evidence of benefit for the health of mothers and babies in populations with values of CS above 
15% (WHO, 2010). With regard to the lower limit, it has been argued that CS rates as low as 
5% could possibly achieve major improvement in maternal outcomes (WHO, 2010). 
 
Given the growing numbers of women who deliver through CS, the choice of the most 
appropriate and effective prophylactic antibiotic is of utmost importance. In such cases, as an 
attempt to reduce the cost for the health system, it would be advisable to have a “simple and 
inexpensive recommended antibiotic regimen” (Cecatti, 2005). A major limitation of the 
available literature on antimicrobial prophylaxis for all types of surgery is the difficulty in 
establishing significant differences in efficacy between prophylactic antimicrobial agents and 
controls (including placebo, no treatment, or other antimicrobial agents) due to study design and 
low surgical site infection (SSI) rates for most procedures (Bratzler et al., 2013). 
 
1.4.1 Caesarean section rates in South Africa 
From a national perspective in South Africa, the CS rates in both the public and private sectors 
appear to be increasing at an alarming rate. CS rates for 2014 were reported to be 24.7% in the 
South African public sector (Day and Gray, 2016). This was considerably higher than the 20.6% 
reported in 2008 (WHO, 2010). The highest CS rates in 2014 were recorded for KwaZulu-Natal 
(29.5%), but rates were also high in Gauteng (25.5%) (Day and Gray, 2016). Higher rates may 
have been recorded in these provinces due to the provision of services to patients referred from 
more rural provinces to the tertiary and regional public hospitals in the better resourced 
provinces. 
 
In  South Africa, CS rates are much higher in the private sector than in the public sector, 
increasing from an alarming rate of 67.5% in 2013 to 70.8% in 2014 (Day and Gray, 2016). 
That said, the availability of studies that provide comparative figures for CS rates in the private 
and public health sectors in South Africa is limited (Naidoo and Moodley, 2009).  
 
A retrospective clinical survey was carried out by Tshibangu et al. (2002), comparing CS 
deliveries in the private sector with those in teaching and public hospitals in Gauteng, South 
Africa. They reported, on average, a CS rate of 57% (11 572 CS in 20 151 deliveries) at six 
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private hospitals over a three-year study period compared to a CS rate of 28% and 19% in one 
teaching hospital and 20 public hospitals respectively.  
 
Current available data from well-resourced countries suggest that morbidity and mortality for 
both mother and baby arising from CS are higher when compared with vaginal delivery 
(Snyman, 2002). In a study by Naidoo and Moodley (2009), CS rates in the private sector in 
KwaZulu-Natal were reported as 60.4%. This elevated CS rate was in accordance with trends 
seen in countries such as those in South America, and was considerably higher than the ideal 
rate of 10 to 15% in low-risk obstetric populations as suggested by the WHO (Naidoo and 
Moodley, 2009). The high rates of CS found in the study by Naidoo and Moodley (2009) are 
probably a reflection of the trend in South Africa.  
 
1.5 Problem statement  
 
The Standard Treatment Guidelines (STGs) issued by the National Department of Health 
(NDOH) are intended to provide practitioners in the public sector with a standardised approach 
to the rational, safe, and effective use of antimicrobial agents for the prevention of surgical-site 
infections (SSIs), based on currently available clinical evidence. There has been evidence of 
non-compliance with the South African national guidelines at Heidelberg Hospital, a district 
level government hospital with a small maternity ward. According to the STGs, the prophylactic 
dose in CS is a single dose of intravenous cefazolin equal to the standard therapeutic dose. A 
second dose is only administered should surgery be prolonged (National Department of Health, 
2012). As highlighted in the peer-reviewed literature, there is no added benefit of using multiple 
doses over single dose of antibiotics for prophylaxis of SSI (Shakya and Sharma,  2010; 
Slobogean et al., 2010) and antibiotic prophylaxis should be given as a single dose (Lyimo et 
al., 2013). 
 
The research question is therefore: in women undergoing Caesarean sections at Heidelberg 
Hospital, is the correct choice of antibiotic and duration of antibiotic prophylaxis being 
administered, in accordance with the current South African National Department of Health 







1.6 Purpose of the research 
The purpose of this study was to highlight the level of non-compliance, with the ultimate aim of 
identifying appropriate remedial action and either reconsideration of local practice or proposals 
for amendment of the NDOH STG. The goal of this retrospective action research was not only 
to elicit knowledge but to also bring about action that will benefit the patients as well the 
healthcare sector. In addition to contributing to the rational and responsible use of medicines, in 
particular antibiotics, through the application of medicines use evaluation (MUE), the purpose 
of the research was to help healthcare facilities to understand, interpret and improve the 
prescribing, administration and use of medications. This study therefore set out to provide 
potential reasons to reconsider the duration of prophylaxis stipulated in the national guidelines, 
which are not specific to CS (being directed at pelvic surgery in general). This MUE provided 
authorised prescribers with feedback on their prescribing patterns with respect to treatment 
protocols in the STG. The study also helped in improving the prescribing and administrations of 
antibiotics at the facility of focus. 
 
1.7 Aim and objectives of the study 
1.7.1 Overall aim 
The aim of this study was to contribute to the rational and responsible use of medicines, in 
particular antibiotics, through the application of medicines use evaluation in order to help 
healthcare facilities to understand, interpret and improve the prescribing, administration and use 
of medications, in a primary level hospital setting. 
1.7.2 Specific objectives 
The specific objectives were: 
• to use Medicine Use Evaluation (MUE) methods to determine the degree to which local 
practice is in compliance with the national STG, with regards to antibiotic prophylaxis 
in CS, over a 3 month period, using retrospective data; 
• to identify the reasons for any identified non-compliance with the national STG, by 
means of local document review and key informant interviews; 
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• to determine the average medicine costs associated with identified non-compliance with 
the national STG; 
• to identify appropriate remedial actions to be taken on the basis of the results obtained 
during the study period; and 
• to utilise the data obtained from the study to review and possibly implement new local 
hospital policies, and if sufficient evidence emerged, to possibly review the national 
STGs. 
1.8 Summary 
This chapter has provided an outline of the relevant issues pertaining to the healthcare systems 
in South Africa as well as the dire need to address maternal mortality. It also provided an 
overview of antibiotic prophylaxis used in Caesarean sections in addition to the importance of 
antimicrobial stewardship programmes. The chapter also included the problem statement, 
purpose of the research, aim and, finally, the specific objectives of the study. The following 
chapters provide a literature review in Chapter 2, the methods used in the study in Chapter 3, a 
presentation of the results in Chapter 4, then an analysis and discussion of the results in Chapter 





CHAPTER II: LITERATURE REVIEW 
2.1 Introduction 
This chapter provides a summary of the available literature that has been reviewed to further 
elaborate on the issues mentioned in Chapter 1. This chapter highlights the risk factors for 
surgical site infections and the common pathogens observed to be causing infections as well as 
give an overview of maternal mortality. The association of HIV and the risk of sepsis are 
highlighted. Emphasis is also placed on the importance of antimicrobial stewardship plans and 
the threat of antibiotic overuse, the challenges to measuring antimicrobial use, the need for 
specific measures in specific settings due to overuse as well as the need for research on 
stewardships. Medicine Use Evaluation is discussed, in terms of the different approaches 
(prospective, concurrent and retrospective). The theoretical framework of the study is also 
provided. The chapter is concluded with a chapter summary. 
 
2.2 Risk factors for surgical site infections 
Caesarean section (CS) wound infections signify a considerable burden to the health system 
(Nwankwo et al., 2012). According to the global estimates of surgical site infections (SSI), they 
account for between 0.5–15% of such infections (Arabashahi and Koohpayezade, 2006), 
varying according to the study population, the study design used to identify the cases, and the 
use of appropriate antibiotic prophylaxis (Mitt et al., 2005). Surgical site infection following CS 
delivery has been implicated as an important cause of morbidity and mortality, leading to an 
increased duration of patient hospitalisation and hospital costs (Oliveira and Ciosak, 2004). 
Deliveries through CS have been associated with escalating rates of maternal morbidity, 
including venous thromboembolism, shock, and haemorrhage (Kuklina et al., 2009). Hence, 
several comprehensive initiatives have been identified by obstetric organisations to lower the 
rates of maternal morbidity by addressing unnecessary CS (Dahlke et al., 2013). 
 
Post-operative length of stay (LOS) following non-obstetric surgery is an important quality 
indicator of inpatient care (Raleigh et al., 2008). With regard to CS deliveries, LOS can also be 
used as a vital metric to evaluate the quality of obstetric care peri-partum and post-partum. 
Sadly, there are limited studies which investigate the risk factors linked to prolonged LOS after 
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a CS delivery. Such data could prove to be beneficial as it could aid ongoing efforts aimed at 
reducing maternal morbidity following CS delivery and could further be helpful for evaluating 
post-CS LOS as a quality measure related to obstetric practice (Blumenfeld et al., 2015). 
 
In the article by Blumenfeld et al. (2015), numerous maternal, medical, and obstetric 
characteristics associated with extended post-partum LOS were recognised: body mass index 
(BMI) ≥ 40 kg/m2; chronic condition such as diabetes, asthma and hypertension, multiple 
pregnancy; ≥ 1 prior Caesarean; and pregnancy-associated hypertensive disorders. Also, 
particular peri-operative morbidities were identified, including general anaesthesia, uterine 
atony, transfusion, hysterectomy, endometritis, ileus, wound complications. Perinatal factors 
associated with extended LOS were preterm delivery, neonatal birth weight. Peri-operative 
morbidities such as ileus, endometritis, and wound complications as well as surgery related 
complications, had the highest risk for prolonged post-partum LOS (Blumenfeld et al., 2015). 
Blumenfeld et al. (2015) also showed that obese women were at higher risk of intra-partum 
morbidity, prolonged LOS, and wound complications when undergoing CS delivery. Similarly, 
a significant association was shown in women with a BMI >35 kg/m2, who were shown to be 
three times more likely to develop a wound infection as opposed to non-obese women (Dhar et 
al., 2014). Increased rates of morbidity associated with post-CS endometritis, ranging from 
16.9% to 32%, have been reported in other studies (Andrews et al., 2003). Other well 
documented independent risk factors for post-CS SSI have included young age, hypertension or 
preeclampsia, chorioamnionitis, nulliparity, less than seven pre-natal visits, extended time from 
rupture of membranes until CS, emergency CS delivery, lack of appropriate antibiotic 
prophylaxis, increased surgical time, birth of twins, as well as excess vaginal manipulation 
(Olsen et al., 2008; Farret et al., 2015). HIV, severe anaemia and gestational diabetes are other 
co- morbidities which are also associated with elevated rates of puerperal infection, particularly 
SSIs (Diamond et al., 1986). There was a significant association reported between hypertension, 
pre-eclampsia and wound infections, as women with these risk factors were three times more 
likely to develop wound infections (Dhar et al., 2014).  
 
No significant association between wound infections and parity has been demonstrated (Dhar et 
al., 2014), although women who have already delivered more than six children were 1.4 times 
more likely to get an infection as opposed to women who were giving birth for the first time or 
had only one child. There is reduced penetration of antibiotics into the skin due to the 
avascularity of adipose tissue. Furthermore, the healing process is delayed as obesity provides 
greater mechanical stress on the wound (Vuolo, 2006). 
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A study by Dhar et al. (2014), found a significant association between premature rupture of 
membranes (PROM) and wound infections, with a four-fold increase. Frequent vaginal 
examinations may also contribute to an increased infection rate. The sterile amniotic fluid can 
possibly be infected if there are infections in the female genital area or the gastrointestinal tract. 
There is also an increased risk of chorioamnionitis as a result of PROM, which can be attributed 
to the loss of the protective effect conferred by the intact foetal membranes. The duration 
between the rupture of the membranes and surgical intervention also has an impact on the rate 
of wound infection. Once the membranes have ruptured, the sterility of the amniotic fluid is lost 
and can therefore serve as a transport medium, encouraging infection of any uterine and/or skin 
incisions (Gould, 2007). 
 
Women with diabetes have been shown to be three to six times more likely to develop wound 
infections than women without diabetes (Nwankwo et al., 2012; Dhar et al., 2014). Fluctuating 
blood glucose levels increase the rate of infection and delays wound healing, by altering the 
ability of leukocytes to control the harmful proliferation of bacteria. 
 
The advantageous effects of appropriate antibiotic prophylaxis in lowering the incidence of 
infection associated with CS are well recognised. Farret et al. (2015), reported that patients who 
were administered 2g of cefazolin intravenously prior to the operation had a 54% reduced the 
risk for any type of SSI. However, in a multivariate-adjusted odds ratio analysis, other variables 
such as extended time for ruptured membranes or the presence of comorbidities were shown to 
also affect the risk of infection. Nonetheless, the authors recommended that prophylaxis be 
administered to selected groups of patients undergoing CS (Farret et al., 2015). 
 
2.3 Deaths due to pregnancy-related sepsis – a cause for concern  
Maternal mortality is tracked by the Confidential Enquiry into Maternal Deaths Committee in 
South Africa (NCCEMD, 2016). The 6th report of this committee was issued in 2016. Non-
pregnancy related infections, obstetric haemorrhage and hypertension were the top three main 
causes of maternal deaths, and accounted more than two-thirds of all maternal deaths. The 
largest category of maternal death was non-pregnancy related infections. However, maternal 
deaths from this cause had significantly decreased over time. Deaths from pregnancy-related 
sepsis (PRS) are defined as “those caused by infections of the genital tract associated with 
viable pregnancies.” There had been a decline in maternal deaths due to PRS between 2002 and 
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2012. The report indicated that 226 deaths from PRS were recorded in 2011-2013. Of these, 117 
occurred after a normal vaginal birth, 88 after CS, 11 after CS complicated by bowel injury and 
10 were attributed to chorioamnionitis. Out of the pregnancy-related sepsis causes, puerperal 
sepsis after normal vaginal delivery (NVD) accounted for 51.8% and puerperal sepsis after CS 
accounted for 38.9% of cases. Lack of appropriately trained medical practitioners was recorded 
as a significant factor in 24% of maternal deaths due to pregnancy-related sepsis (NCCEMD, 
2016).  
 
The Institutional Maternal Mortality Ratio (iMMR) attributed to PRS declined from 12.1 per 
100 000 live births in 2002-2004 to 8.0 in 2011-2013. The iMMR causally related to the mode 
of delivery was three times higher for operative delivery, at 185.8 per 100 000 live births for CS 
compared to 66.6 per 100 000 live births for vaginal birth (NCCEMD, 2016). 
 
There was a reduction from 4.1 per 100 000 live births in 2008-2010 to 3.1 in 2011-2013 with 
regard to the iMMR for deaths after Caesarean section (excluding cases of bowel injury). 
“Forty-three per cent of PRS deaths in 2011-2013 occurred at regional hospitals, and 30% 
occurred at district hospitals.” Limpopo, Mpumalanga and North-West were the three provinces 
with the highest iMMRs for PRS. While Gauteng and the Western Cape were among the two 
provinces with the lowest iMMRs for PRS. HIV status was known in 206 of the deceased 
women, of whom 137 (67%) were known to be living with HIV (NCCEMD, 2016). 
 
It has been suggested that particular emphasis needs to be placed on developing new strategies 
for the management of high-risk patients and improving surgical practices to reduce the risk of 
extended LOS following CS (Blumenfeld et al., 2015). Thus, prevention of such infections 
should be a healthcare priority in all countries. As infection continues to be a growing problem, 
there has also been a call for implementation of SSI surveillance during and after surgeries in 
order to attain a standardised measure of incidence (Gould, 2007; Dhar et al., 2014). 
 
2.4 HIV and the risk of sepsis 
Sub-Saharan Africa has been the area most affected by the HIV epidemic globally. High levels 
of HIV and the possible risk of dying due to complications of pregnancy have affected several 
women of child-bearing age in this region. There have been reports from clinicians practising in 
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high HIV prevalence settings that obstetric complications are common in women living with 
HIV. However, the supporting evidence is not clear (Verkuyl, 1995). 
 
Sepsis is considered the most common complication yet the association between post-operative 
sepsis and the various variables implicated may not be so straight forward. For example, it 
seems plausible to expect an association between HIV infection and post-CS sepsis, however 
Rodriguez et al. (2001) demonstrated that there was no difference between post-operative 
morbidity among HIV-infected women undergoing CS and those in the control group. However, 
Moodliar et al. (2007) confirmed in a study carried out in a setting with high HIV prevalence 
rates that complications associated with CS are common, 14.2% of CS were associated with a 
complication. On the other hand, a systematic review which investigated the effects of 
pregnancy on HIV progression and survival did not find any clear evidence that pregnancy 
caused a rapid progression to an HIV-related illness or a drop in CD4 count to less than 200 
cells per cubic millilitre (French and Brocklehurst, 1998). 
 
A systematic review carried out by Calvert and Ronsmans (2013), to establish whether HIV-
infected women are at increased risk of direct obstetric complications, found that studies 
including vaginal and CS deliveries have indicated that HIV-infected women had over three 
times the risk of puerperal sepsis compared with uninfected women. HIV-positive women were 
more susceptible to infections including puerperal sepsis after surgical procedures due to their 
immuno-compromised status and overall health compared to uninfected women (Graham and 
Hussein, 2003). It has been suggested that HIV-related thrombocytopenia, a condition in which 
there is a reduced platelet count in the blood, may lead to an increased risk of haemorrhage 
(Calvert and Ronsmans, 2013). Moreover, social factors like insufficient access to healthcare 
play a role in increasing a woman’s risk of obstetric complications, and may be aggravated in 
HIV-infected women as a result of the discrimination and stigma faced by these women in 
certain settings (Calvert and Ronsmans, 2013). 
 
An association between HIV and both uterine rupture and prolonged labour has been 
demonstrated (Calvert and Ronsmans, 2013). The higher risk of intrauterine infections 
associated with HIV is understandable, as the immunocompromised state related to HIV 
increases susceptibility to infections (Van Dillen et al., 2010). The risk of experiencing 
postpartum infections maybe increased by Caesarean sections. The authors indicated that the 
risk of intrauterine infections was higher women who were HIV-infected and persisted among 
those undergoing CS deliveries. There is still uncertainty whether the increased risk of 
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endometritis and puerperal sepsis in the intra- and post-partum period is directly related to the 
pregnancy or indirectly linked to HIV or AIDS-associated infections (Calvert and Ronsmans, 
2013). 
 
There are limited studies conducted on the causes of death in pregnant or post-partum women 
by HIV status, with the exception of the South African Confidential Enquiries. In the 2011-2013 
Confidential Enquiry report, 60.6% of women who died from pregnancy-related infections were 
HIV-positive, while 89% of maternal deaths attributed to non-pregnancy-related infections were 
in women living with HIV (NCCEMD, 2016). 
 
In a study by Ferrero and Bentivoglio (2003) the various risk factors listed were: HIV infection 
associated factors (CD4+ lymphocyte count, mode of HIV acquisition, antiretroviral therapy 
during pregnancy), obstetrical factors (emergency CS, ruptured membranes, preterm delivery) 
and maternal factors (age, obesity, parity). Critically, in this study, HIV-infected women were 
shown to have an increased risk of postoperative morbidity regardless of whether or not a single 
dose of intravenous prophylactic antibiotic (generally a cephalosporin) was administered at the 
time of the CS (Ferrero and Bentivoglio, 2003). However, it must be noted that there are limited 
data on the complications among HIV-infected women undergoing CS delivery, but there 
appears to be a consistent finding of an increased complication rate when compared to HIV-
uninfected women (Robinson et al., 1987; Semprini et al., 1995). 
 
2.5 Antibiotic prophylaxis in Caesarean sections 
CS is one of the most common surgical procedures performed in medical practice worldwide. 
CS births are the most important known common factor that has been linked with post-partum 
bacterial infections, with a reported rate of wound infection between 1– and as much as 25% 
(Chaim et al., 2000; Morisaki et al., 2014; Henderson and Love, 1995). There is a 5–20 times 
greater risk of developing post-partum infections after CS delivery compared to vaginal delivery 
(Lamont et al., 2011). Nonetheless, clear evidence points to a reduction in the risk of 
endometritis and other bacterial infections, even in low-risk (before labour and with intact 
membranes) pregnancies, when prophylactic antibiotics are utilised in CS (Smaill and Gyte, 
2010). The application of universal prophylactic antibiotics in obstetrics has therefore been 
widely accepted in guidelines for several countries, such as the United States (US) and 
numerous Asian countries (Morisaki et al., 2014). However, there are reports of barriers that 
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exist to providing effective antibiotic prophylaxis in all CS deliveries (Salim et al., 2011). There 
are also continual discussions about the potential need for modifying prophylaxis regimens in 
particular high- or low-risk groups (Lamont et al., 2011, Morisaki et al., 2014). Based on 
studies in the US, there is an increased risk of bacterial infections in socially disadvantaged 
populations (Creanga et al., 2012). In low-income settings, improving the safety and care 
provided when performing a CS can lead to improvements in maternal and neonatal outcomes, 
which is in keeping with the Millennium Development Goals and now the Sustainable 
Development Goals (United Nations, 2015b).  
 
As noted, surgical site infections are a common complication of obstetric and gynaecological 
procedures, and so antimicrobials are commonly prescribed prophylactically, both pre-
operatively and post-operatively, for procedures in Obstetrics and Gynaecology (Warnecke et 
al., 1982). The judicious use of antibiotics can prevent post-partum infection of the mother and 
neonate and reduce the incidence of adverse drug reactions (Liu et al., 2016). Indiscriminate use 
of antibiotics may result in the appearance of drug-resistant organisms (Smaill and Grivell, 
2014). Antimicrobial usage in the above setting therefore becomes inevitable, but should be 
restricted in order to avoid excessive ecological pressure, leading to resistance. The rational use 
of antimicrobials in women of child-bearing age is important because it affects this population 
as well as their offspring.  
 
In a study by Morisaki et al. (2014) the authors suggested that there may be a relation between 
the coverage of antibiotic prophylaxis in women having CS and the perception of the 
importance of guidelines and clinical audits in the facility. The authors further stated that even 
though obstetricians are seemingly aware of the increased risk of infection in most maternal 
complications when antibiotic prophylaxis is administered, there may also be a trend to overuse 
prophylaxis in scheduled CS deliveries as it is incorporated in the routine clinical protocol 
(Morisaki et al., 2014). 
 
Several studies have verified the efficacy of antibiotic prophylaxis in the reduction of post-CS 
infectious morbidity (Enkin et al., 1989). Debates surrounding the duration of therapy and cost 
containment remain controversial. There is sufficient evidence of the need for and effectiveness 
of antibiotic prophylaxis in the prevention of SSIs. Hence the current debate places emphasis on 
the choice and timing of antimicrobial prophylaxis administration (Lamont et al., 2011). 
Evidence-based guidelines recommend the use of prophylactic antibiotics before surgical 
incision. In order to be effective, a prophylactic agent only needs to be present at the time of 
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bacterial contamination (Ledger, 1986). As indicated in a study by Gonik and McGregor (1994), 
in women that have had a CS and presented with an infection post-CS, additional antibiotic 
therapy was only initiated after the diagnostic studies were completed if deemed necessary by 
the attending physician (Gonik and McGregor, 1994). An exception is made for CS delivery, 
where narrow-range antibiotics are administered after umbilical cord clamping due to putative 
neonatal benefit. However, recent evidence supports the use of pre-incision, broad-spectrum 
antibiotics, which result in a lower rate of maternal morbidity with no disadvantage to the 
neonate (Lamont et al., 2011).  
 
2.5.1 Selection of prophylactic antibiotics 
In patients with known risk factors undergoing CS, infectious morbidity is reasonably common, 
this being in the form of post-partum endometritis, wound infection, or urinary-tract infection 
(Enkin et al., 1989). Ureaplasmaspecies (spp.), Mycoplasma spp., anaerobes or Gardnerella 
vaginalis are some of the common causative organisms responsible for polymicrobial bacterial 
vaginosis (Andrews et al., 1995; Martens et al., 1995; Watts et al., 1990) and which can be 
isolated from the amniotic fluid and the chorioamnion during CS (Keski-Nisula et al., 1997). 
There is a three- to eight-fold increased risk of endometritis and bacterial vaginosis should these 
causative organisms be detected post-CS (Andrews et al., 1995; Watts et al., 1990). Skin 
contaminants, as well as organisms responsible for bacterial vaginosis, make surgical wounds 
very susceptible to infection (Emmons et al., 1988). The use of first-generation cephalosporins 
such as cefazolin provides good antibiotic activity against species of Ureaplasma and 
Mycoplasma (ACOG, 2003), but may lead to an increase in resistant anaerobic organisms 
(Newton and Wallace, 1998). Hence the rationale for adding other antimicrobial agents, such as 
metronidazole, clindamycin or azithromycin, is to provide a more extensive cover and 
particularly cover for anaerobes (Lamont et al., 2011). The broad-spectrum antibiotics that have 
been evaluated are mainly single-agent extended-range penicillins, or second- or third-
generation cephalosporins, but these have shown no advantage (Hopkins and Smaill, 2000). 
 
Numerous studies have acknowledged the efficacy of a variety of regimens for antibiotic 
prophylaxis to reduce post-operative infectious morbidity. Although this general approach has 
led to significant reductions in the duration of hospitalisation (Duff, 1987), further attempts at 
cost containment have encouraged the recommendation to use less expensive (and less broad-
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spectrum) antimicrobial agents and to reduce the number of peri-operative antibiotic doses (Faro 
et al., 1990). 
 
In a review by Cecatti (2005) it was found that, there was a homogenous protective effect in 
all women undergoing CS, despite the regimen used or study carried out. The author was 
thus persuaded of the need for all women undergoing CS to receive antibiotic prophylaxis in 
order to reduce the incidence of SSIs. Since there are similarities in the effectiveness of 
ampicillin and first generation cephalosporins, there is no justification for utilising agents 
with a broader spectrum or multiple antibiotics. However, there is still uncertainty, and a 
degree of variability in practice, with regard to optimal timing of administration and the 
number of doses. 
 
2.5.2 Duration and dosing of prophylactic antibiotics 
According to the current NDOH STG, the prophylactic dose in surgical prophylaxis is a single 
dose equal to the standard therapeutic dose. A second dose is only given if surgery is prolonged 
(NDOH, 2012). For all patients, intra-operative re-dosing is needed to ensure adequate serum 
and tissue concentrations of the antimicrobial if the duration of the procedure exceeds two half-
lives of the drug or there is excessive blood loss during the procedure (Bratzler et al., 2013). 
Published guidelines and such as those from the American Society of Health-System 
Pharmacists (ASHP) have also been noted as recommending the use of cefazolin in CS (Bratzler 
et al., 2013). According to the Zimbabwe Medicines Formulary and Treatment Guidelines 2011, 
women undergoing CS should receive a single dose of 1g ceftriaxone IV (Gidiri and Ziruma, 
2014). Gidiri and Ziruma (2014) conducted a randomised clinical trial that compared the current 
Zimbabwean practice of repeated dose prophylactic antibiotics to a proposed single dose regime 
of prophylactic antibiotics for women undergoing CS. The authors concluded that whether a 
single dose of prophylaxis was given or a week’s course of antibiotics, the regimens were 
equivalent in preventing infection and reported that there it was unnecessary to subject women 
to week-long antibiotics as this also increased nurses’ workload. As these authors stated: 
“Clinicians have developed fears based on anecdotes of post-surgical infection and have 
gradually moved away from evidence-based regimens of antibiotic prophylaxis and adopted 
therapeutic regimens” (Gidiri and Ziruma, 2014). No added benefit of using multiple doses over 
single dose of antibiotics for prophylaxis of SSI has also been reported in previous studies 
(Shakya and Sharma, 2010; Slobogean et al., 2010). It is therefore recommended that single 
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dose antibiotic prophylaxis be administered pre-operatively for emergency and elective CS. The 
1998 Swedish and Norwegian consensus guidelines on the use of antibiotic prophylaxis in 
surgery also support this approach, which states that surgeons should be conservative when 
selecting antibiotics (Anonymous, 1998). 
 
The cost implications with the use of antibiotics beyond the recommended time are important to 
consider, especially in resource-limited settings. A multiple-dose regime will necessarily be 
associated with higher cost compared to a single-dose regime, not just in terms of acquisition 
costs but also in terms of staff time. The use of a single-dose regime would be expected to 
reduce work load (Gidiri and Ziruma, 2014). The shortage of healthcare workers is a serious 
problem in many resource-limited settings. In addition, the effect on susceptibility patterns of 
the common bacteria causing SSIs should be considered.  
 
By definition, the purpose of antimicrobial prophylaxis is to reduce bacterial colonisation and 
contamination at the time of surgery, and therefore allow the patient’s immune system to 
overcome the threat of infection (Ledger, 1986; Kaimal et al., 2008; Mangram et al., 1999). 
Hence the prophylactic agent should be given empirically to ensure that adequate tissue 
concentrations are present during the time of CS. Since CS procedures very seldom exceed an 
hour, relatively short half-life agents should be efficacious (Gonik and McGregor, 1994). 
 
Over the years, the administration of prophylactic antibiotics has become the responsibility of 
the anaesthesiologist. Therefore, there is a growing need for anaesthesiologists to understand the 
rationale behind antibiotic prophylaxis regimen choices (Dlamini et al., 2015). In a study 
conducted by Dlamini et al (2015) the authors highlighted the importance of the timing of 
prophylaxis. It was found that the overall risk of postoperative infections, in particular 
endometritis, was significantly lower when prophylaxis was administered within one hour 
before skin incision compared to those who received prophylaxis after skin incision. To meet 
this timing, anaesthesiologists need to prescribe the prophylactic antibiotics in time, but also 
ensure their timeous administration (by themselves or by ward or theatre nurses). 
 
2.5.3 Timing of antibiotic prophylaxis 
The controversial issue of whether antibiotic prophylaxis for CS should be administered prior to 
the skin incision or at the time of the umbilical cord clamping remains. Conventionally, the 
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reason for delaying prophylaxis was to avoid masking a neonatal infection and to prevent an 
unnecessary septic workup. However, in recent studies there has been no increase in neonatal 
sepsis, sepsis investigations, or length of stay demonstrated with pre-incision administration 
(Costantine et al., 2008). A meta-analysis published in 2008 by Constantine et al. supports 
antibiotic prophylaxis being administered prior to CS incision to reduce total infectious 
morbidity without adverse effects on neonatal outcomes. Despite current studies suggesting the 
possibility of more long-term effects of antibiotic prophylaxis on neonates, further long term 
follow up studies on neonates exposed to prophylactic antibiotics are still required (Dlamini et 
al., 2015). As a result, in 2010, the American College of Obstetricians and Gynecologists 
suggested that antibiotic prophylaxis be administered within an hour before commencement of 
the surgery (ACOG., 2010). In the event of an emergency CS delivery, antibiotic prophylaxis 
should be initiated immediately (Dlamini et al., 2015). 
 
With respect to the timing of antimicrobial prophylaxis, the occurrence of errors has been 
reported by a multitude of investigators over the past decade. In a retrospective review of 2651 
specified surgical procedures (aortic grafts, hip replacements, or colon resections) performed 
during 1993 at 44 hospitals, the Healthcare Quality Improvement Project of New York State 
reported that 27%–54% of all patients did not receive antimicrobial prophylaxis in a timely 
fashion (Silver et al., 1996). Several countries, such as the United States, Netherlands, Spain, 
Israel, Canada, India, and Brazil, have produced a plethora of similar findings (Matuschka et al., 
1997). There have been various approaches to ensure optimal timing of prophylactic antibiotic 
administration and this aspect has been well investigated by healthcare epidemiologists.  
 
Errors in antimicrobial prophylaxis are unlikely to generate a great deal of awareness, 
considering the increased expenditure on surgical site infections (Kirkland et al., 1999). 
However, as there is strong evidence that lower rates of infection can be achieved with 
programmes to optimise antimicrobial prophylaxis, this problem deserves high priority (Burke, 
2001). However, as is the case with all medical errors, a non-punitive approach is warranted. 
More emphasis on evaluating the root causes of such errors, rather than on the mistakes of 
individual surgeons, is needed (Burke, 2001).  
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2.6 Importance of stewardship plans and the threat of antibiotic overuse 
“Antimicrobial stewardship acts at an organisational level and defines collective strategies to 
optimise antimicrobial prescribing through sustainable changes in practice”, as has been stated 
by Gottlieb and Nimmo (2011). Antimicrobial stewardship programmes are aimed at optimising 
the usage of antimicrobials to achieve the best clinical outcomes, while attempting to reduce 
adverse events and limit selective pressures that drive the emergence of resistance 
(SHEA,IDSA,PIDS, 2012). Therefore, all healthcare facilities should have antimicrobial 
stewardship programmes implemented in their institutions, as both a patient safety issue and a 
public health imperative (SHEA,IDSA,PIDS, 2012). The rising ineffectiveness of once-reliable 
antibiotics has forced many healthcare professionals to utilise alternatives that are much more 
toxic, more costly and less likely to be orally available, thus putting added pressure on an 
already highly strained hospital system. Also, when compared to susceptible bacteria, antibiotic-
resistant organisms are associated with increased patient morbidity and mortality resulting in 
increased costs of healthcare (WHO, 2001; Gottlieb and Nimmo, 2011). 
 
The introduction of antibiotics was one of the most significant developments in modern 
medicine. Their availability has helped in the treatment of increasingly complex care. The 
ability to control infections through the use of antimicrobial agents has had a major impact in all 
clinical areas, but particularly in surgery, transplantation medicine, oncology, and intensive care 
medicine. In 1945, penicillin resistance in Staphylococcus aureus was first discovered followed 
by the emergence of resistance to methicillin in 1961 (Barrett et al., 1968). By 1999, methicillin 
resistance in S. aureus was found in more than 53% of isolates taken from patients in intensive 
care units in a US surveillance system (CDC, 2000). 
 
While the emergence of antimicrobial resistance has been at the forefront, it has long been 
assumed that this issue would be addressed by the ongoing development of new compounds. 
However, over time there has been a decline in the development of new antibiotics, stressing 
that this approach cannot be relied upon (WHO, 2001; Gottlieb and Nimmo, 2011). Resistant 
infections not only result in increased morbidity and mortality but also noticeably increase 
healthcare costs (Boucher et al., 2009; Lautenbach et al., 2006). In order to control the 
emergence of resistant organisms, more comprehensive approaches will be required. Such 
approaches will need to ensure that adequate and appropriate therapeutic medicines are 
available, the availability of diagnostic tools to rapidly and reliably detect particular infection 
causing organisms as well as their antimicrobial susceptibilities are developed, and continuous 
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monitoring and promotion of vigorous infection control and antimicrobial stewardship 
programmes are in place (SHEA,IDSA,PIDS, 2012).  
 
Agricultural practices, in which the use of antibiotics for prophylaxis and growth promotion is 
involved adds to the ecological pressure driving the emergence of resistance. As reported in 
numerous studies, a significant proportion of antibiotic use is unnecessary and the usage clearly 
varies between countries regardless of having similar clinical outcomes (WHO, 2001). 
 
2.6.1 Challenges to measuring antimicrobial use 
In order to address the issues that surround antibiotic use, it is important to measure the degree 
of antimicrobial resistance in community and healthcare-associated infections and outcomes of 
any interventions designed. There is currently a lot of variation in the systems used for data 
collection and collation between countries and there is limited coordination at an international 
level. It is of utmost importance to have a surveillance programme to measure antimicrobial 
resistance as well as to track antimicrobial utilisation (Gottlieb and Nimmo, 2011). 
 
The provision of education to the public together with the various sectors (medical, veterinary 
and public health) is vital if appropriate use of antibiotics is to be achieved. However, education 
campaigns and guidelines alone are inadequate unless they are coupled with sustained 
interventions such as audit and feedback methods or a system in which proactive steps are taken 
to aid prescribing and having interventions that tackle poor performance (Dellit et al., 2007; 
Gottlieb and Nimmo, 2011). 
 
A number of countries have responded. For example, in 2011, the Australasian Society for 
Infectious Diseases and the Australian Society for Antimicrobials convened an Antimicrobial 
Resistance Summit. They proposed that educational initiatives needed to place more emphasis 
on the relevance if antimicrobial resistance to public health. They also emphasised that ASPs 
needed to be based on national guidelines and local epidemiology. They emphasised that ASPs 
needed to be implemented by a multidisciplinary team, ideally including infection prevention 
units, microbiologists, pharmacists and clinicians. This team needs strong support from senior 
hospital management and access to the necessary information technology. Other bodies have 
emphasised that the necessary procedures need to be in place to measure and monitor 
antimicrobial use at the institutional level, in order to enable internal benchmarking 
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(SHEA,IDSA,PIDS, 2012). ASPs should not be limited to healthcare facilities and should 
extend to community care and long-term care facilities. The creation of a well-resourced 
national body to govern educational activities and antibiotic stewardship programs would 
provide more control (Gottlieb and Nimmo, 2011). 
 
EARS-Net (the European Antimicrobial Resistance Surveillance Network) and ESAC-Net 
(European Surveillance of Antimicrobial Consumption Network) are European networks which 
monitor surveillance systems nationally and are led by the European Centre for Disease 
Prevention and Control (ECDC) (ECDC, 2016). EARS-Net is responsible for documenting the 
prevalence and development of antibiotic resistance in Europe. The onus is upon each country 
to gather and collate their data and report it to a central database at ECDC annually. There 
should be careful interpretation when comparing resistance in European countries as the 
difference in sampling procedures may affect the results. Certain countries take blood cultures 
more often from patients whereas others may only focus on complicated cases. As a result, a 
distorted image of the resistance situation may be presented. ESAC-Net collects and analyses 
data on antimicrobial consumption in the community as well as the hospital sector. This data is 
then disseminated and used to provide feedback to European countries on indicators of 
antimicrobial consumption in order to monitor the progress towards the cautious use of 
antimicrobials (ECDC, 2016). 
 
In Sweden, the foundation of STRAMA, a well-coordinated national strategy, was initiated due 
to the rapid emergence of resistance to penicillin among pneumococci. STRAMA has been 
critical to ensuring that measurement methods are of high quality and consistently applied. 
ResNet is a point prevalence measurement, which is representative of the time period in which 
the measurements were carried out. Due to the participation of all laboratories the design of 
ResNet is able to monitor resistance across the entire country. One particular challenge that this 
software presents is that aggregated data per laboratory for bacterial species and antibiotic are 
received and presented. As a result this does not allow the detection of the prevalence of multi-
resistant strains. It is precisely this level of information that is needed for the development or 
updating of local treatment guidelines. Previously, such data could only be retrieved directly 
from each hospital’s records. However, with complete coverage of all laboratories in Sweden, 
such data are now available to the relevant healthcare authorities, and can inform guideline 




2.6.2 The need for specific measures in specific settings 
The implementation of effective regulatory controls is a vital aspect of reducing indiscriminate 
use of antibiotics and keeping levels of antimicrobial resistance low in both human and animal 
settings. The Australasian Society for Infectious Diseases and the Australian Society for 
Antimicrobials has highlighted the need for a comprehensive national antimicrobial resistance 
surveillance to monitor the extent of resistance present, in which bacteria and where (SHEA, 
IDSA, PIDS, 2012). Areas that should be monitored include medical (hospital and community) 
and veterinary areas, as well as agriculture (including imported food). There should be 
standardisation of methods used in resistance testing wherever possible to allow for comparison 
and pooling of data. An example is the standardisation of minimum inhibitory concentration 
breakpoints (Gottlieb and Nimmo, 2011). 
 
Antibiotic usage surveillance is another area where additional focus is warranted. A 
comprehensive national monitoring and audit system focusing on all areas of antibiotic usage is 
essential. Approaches that have been suggested include comprehensive monitoring of the 
antibiotics used in all hospitals (where electronic systems are more likely to be present), 
sampling that is representative of community prescribing, and collection of distribution data 
from suppliers to the agricultural market. In addition, point-prevalence surveys are needed, in 
which the diagnosis is compared with the prescriptions issued. In order to ensure benchmarking 
and transparency, it has been recommended that hospitals voluntarily identify themselves in 
surveillance programmes (Gottlieb and Nimmo, 2011). 
 
2.6.3 The need for research on antimicrobial stewardship 
There are significant gaps in existing knowledge and understanding of antimicrobial resistance 
and the interventions that are effective in limiting both the emergence and the transmission of 
resistance. Research is required for the development of a more standardised explanation of both 
the appropriate and redundant overuse and abuse of antimicrobial therapy, as well as clear and 
unambiguous measures of such use (SHEA,IDSA,PIDS, 2012). Research is needed on patient-
centred outcomes in order to determine the most effective and cost-efficient execution of 
interventions in various healthcare settings. Thus far, research has been hampered by poor study 
design and an absence of standardised definitions (SHEA,IDSA,PIDS, 2012). Research is also 
needed on the development and validation of clear and well-defined processes and measures 
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that can be used to assess the impact of antimicrobial stewardship interventions in facilities as 
well as across healthcare settings (SHEA,IDSA,PIDS, 2012). 
 
2.6.4 The role of pharmacists in ASPs 
Pharmacists have been placed at the forefront of ASPs with responsibility for monitoring and 
controlling antibiotic use. As a means of saving on costs, the pharmacy department was 
typically the first to initiate one of many ASP-like interventions. Pharmacists are well suited for 
this task due to their role in processing medication orders and their expertise with the hospital 
formulary. Different hospital-based pharmacists may serve a range of roles in these 
programmes. Pharmacists in hospitals are able to notify prescribers when restricted items are 
prescribed and make them aware when authorisation is needed. Apart from being the custodians 
of medicines, they may also identify prescriptions which need to be reviewed by infectious 
diseases specialists and flag these prescriptions. However, due to the diverse responsibilities 
shouldered by pharmacists, there is rarely sufficient time allowed for a comprehensive review of 
antimicrobial therapy. In addition, not all pharmacists are equipped with adequate knowledge 
and training in infectious diseases to provide recommendations comfortably for complex cases. 
Thus, having a clinical pharmacist with specialised knowledge and training in infectious 
diseases working full or part-time on the administration of the ASP will be an added benefit 
(MacDougall and Polk, 2005). 
 
Both pharmacists and professional nurses can be seen as existing resources that are more than 
capable of co-ordinating and implementing ASPs, as well as improving patient outcomes in 
both the in-patient and out-patient settings (Schellack et al., 2016). It is essential in the South 
African context, where health human resources are scarce, to utilise these resources. Much of 
the attention to date has been placed on promoting optimal antimicrobial prescribing, and has 
thus been aimed predominantly at hospital-based medical practitioners. However, a 
comprehensive approach is needed, engaging all appropriate healthcare professionals. Nurses 
play an important role “in monitoring compliance with institutional guidelines and best practice, 
monitoring for drug allergies and side-effects, obtaining and reporting of therapeutic levels, 
management and administration of medicines with mixed dosages, e.g. insulin, and ensuring 
timely and correct administration of antimicrobials” (Schellack et al., 2016). Through the 
integration of nurses in ASPs, there can be a shared sense of responsibility in the care of 
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patients. This also allows nurses increased professional autonomy, and corrects the 
misconception that ASPs are outside the scope of nursing responsibility and expertise.  
 
Recently, Brink et al. (2016), have reported a significant decline (18.1%) in overall antibiotic 
usage as a result of interventions implemented by pharmacists, coupled with communication 
aimed at prescribers, in a South African private sector setting.  
 
 
2.7 Medicine Use Evaluation as a concept 
 
A Medicines Use Evaluation (MUE) is “defined as an authorized, structured, ongoing review of 
prescribing, dispensing and use of medication” (Navarro, 2009). It is a continuous, methodical 
process that is designed to facilitate the appropriate and effective use of medications (Navarro, 
2009). This process encompasses a review against predetermined criteria; followed by adequate 
changes to the treatment should these criteria not be met. There is constant monitoring of 
patients’ medication history before, during and after dispensing in order to achieve positive 
outcomes which will be beneficial to the patient. These evaluations can serve as a quality 
assurance measure to provide corrective action, prescriber feedback and further evaluations 
(AMCP, 2009). 
 
MUE can be classified into three major categories (AMCP, 2009): 
• Prospective – “evaluation of a patient's drug therapy before medication is dispensed” 
• Concurrent – “ongoing monitoring of drug therapy during the course of treatment”  
• Retrospective – “review of drug therapy after the patient has received the medication” 
 
Each of these types is explored in some detail. 
 
2.7.1 Prospective Review 
 
This method of evaluation enables the pharmacist to identify and resolve problems before the 
patient has received the medication and is practised routinely by pharmacists through the 
assessment of prescription medication dosages and directions for use, while providing a review 
of patient information for possible drug interactions or duplicate therapy (Navarro, 2009). 
Prospective review places responsibility on the healthcare provider to evaluate prescriptions and 
proactively identify and resolve potential medicine-patient problems. It therefore allows the 
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pharmacist the opportunity to interact with patients and communicate with members of the 
healthcare team to work on a treatment plan for each patient. Furthermore, in the community 
pharmacy and institutional settings, pharmacists will be able to determine the appropriateness of 
the prescribed medicines therapy as they will be able to assess the prescription order at the time 
of dispensing and use information from the patient's medical or pharmacy record. In the event 
that opportunities for improved patient care are identified, the pharmacist can contact the 
prescriber to discuss alternative treatment options (Navarro, 2009). 
 
High quality data can be obtained with strong validity. However, prospective review can be 
expensive, as the process is time-consuming to design and implement (Kalogeropoulos, 2014). 
2.7.2 Concurrent review 
In concurrent review, the review is conducted during the course of treatment, as it presents 
pharmacists with the opportunity to notify prescribers of the potential problems and intervene in 
areas such as drug-drug interactions, duplicate therapy, over- or under-utilisation and excessive 
or insufficient dosing. Concurrent review enables the patient’s treatment plan to be modified in 
real time, if necessary. In an era of electronic prescribing, this process enables pharmacists to 
make interventions prior to the medicine being dispensed. It is vital that pharmacists have 
access to complete and current medicines and allergy records for the patient, in addition to 
adequate knowledge of appropriate therapeutic interchanges for patients. Healthcare 
practitioners are able to offer education on the proper use of medications and determine if there 
are specific patient needs that need to be addressed through adequate patient counseling 
(Navarro, 2009). 
 
2.7.3 Retrospective Review 
 
A retrospective review enables pharmacists to identify patterns in prescribing, dispensing or 
administering medicines. As a measure to avoid a repetition of inappropriate medication use, 
prospective standards and target interventions can be developed by monitoring current patterns 
of medication use. It is a relatively inexpensive process, as results and data can be quickly 
generated. However there is a risk for potential bias as there can be missing data and 
unmeasured confounders (Kalogeropoulos, 2014). Retrospective review may aid prescribers in 




2.7.4 The importance of MUE 
 
MUE programmes play a major role in helping healthcare systems “understand, interpret, 
evaluate and improve the prescribing, administration and use of medicines” (AMCP, 2009). In 
particular, they appeal to funders as they can be used to foster more efficient use of limited 
healthcare resources. Pharmacists are able to contribute to MUEs due to their knowledge and 
expertise in the management of medicines therapy. MUEs also encourage a multi-disciplinary 
team approach to the care of patients (AMCP, 2009). 
 
According to the WHO, the most important aim of medicines utilisation research is to contribute 
to the rational use of medicines in populations. Without having knowledge of the prescribing 
patterns of medicines used, it is difficult to initiate a discussion on rational medicines use or to 
suggest measures to improve prescribing habits. The supply of information on the past 
performance of prescribers is essential to any auditing system. Medicines utilisation research 
alone cannot provide answers, but it can significantly assist in the rational use of medicines 
(WHO, 2003). Pharmacists participating in medicines utilisation research, such as MUEs, can 
have a direct impact on improving the quality of care for patients individually and as 
populations (AMCP, 2009). 
 
2.7.5 Monitoring antibiotic prophylaxis using a retrospective MUE 
 
Retrospective MUE evaluates therapy after the patient has received the medication with the aim 
of detecting patterns in prescribing, dispensing or administering of medicines. Some of the 
common issues that such a programme can address are: appropriate generic use, clinical 
abuse/misuse, drug-disease contraindications, drug-drug interactions, inappropriate duration of 
treatment, incorrect dosage, use of on-formulary (essential medicines list) medications 
whenever appropriate, over- and under-utilisation, therapeutic appropriateness and/or 
duplication. For the purpose of monitoring current patterns of antimicrobial prophylaxis use, 
prospective standards can be used to detect inappropriate medication use and therefore target 
interventions to prevent recurrence. The outcomes of such an evaluation may aid prescribers in 
improving medicines use and patient care by initiating corrective action (AMCP, 2009).  
 
As the development and use of MUEs continues, a more multidisciplinary approach involving a 
range of healthcare professionals will be needed in order to move closer to the ideal of 
comprehensive healthcare utilisation evaluation (AMCP, 2009; Navarro, 2009).  
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2.8 Theoretical framework  
This research is located within the theoretical framework of Pharmaceutical Care, as elucidated 
by Hepler and Strand (1990). Pharmaceutical care was defined by Hepler and Strand as the 
"responsible provision of drug therapy for the purpose of achieving definite outcomes that 
improve a patient's quality of life." At the time of the development of the concept, Hepler and 
Strand pointed to the high burden posed by adverse drug reactions (ADRs). They noted that, in 
1987, an estimated 12 000 deaths and 15 000 hospitalizations were reported to the FDA as a 
result of ADRs. They therefore emphasised the social responsibility of the pharmacy profession 
in reducing preventable drug-related morbidity and mortality, reducing the number of ADRs, 
the length of hospital stays, and ultimately the cost of care. At the time, they called for new 
practice standards, but also the need to establish mutual relationships with other health-care 
professions. The patient outcomes that pharmacists seek to achieve are (1) cure of a patient’s 
disease, (2) elimination or reduction of a patient’s symptomatology, (3) arresting or slowing of a 
disease process, or (4) prevention of a disease or symptomatology. In order to achieve these, 
pharmacists are enjoined to (1) identify potential and actual medication-related problems, (2) 
resolve actual medication-related problems, and (3) prevent potential medication-related 
problems. 
 
Hepler and Strand identified the following categories of medication-related problems: 
•“Untreated indications. The patient has a medical problem that requires medication therapy (an 
indication for medication use) but is not receiving a medication for that indication. 
• Improper drug selection. The patient has a medication indication but is taking the wrong 
medication. 
• Sub therapeutic dosage. The patient has a medical problem that is being treated with too little 
of the correct medication. 
• Failure to receive medication. The patient has a medical problem that is the result of not 
receiving a medication (e.g., for pharmaceutical, psychological, sociological, or economic 
reasons). 
• Over dosage. The patient has a medical problem that is being treated with too much of the 
correct medication (toxicity). 
• Adverse drug reactions. The patient has a medical problem that is the result of an adverse drug 
reaction or adverse effect. 
• Drug interactions. The patient has a medical problem that is the result of a drug–drug, drug–
food, or drug–laboratory test interaction. 
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• Medication use without indication. The patient is taking a medication for no medically valid 
indication.” (Hepler and Strand, 1990). 
 
In unpacking the demands of this model of professional action, the American Society of 
Hospital Pharmacists stated: “In the provision of pharmaceutical care, pharmacists use their 
unique perspective and knowledge of medication therapy to evaluate patients’ actual and 
potential medication-related problems. To do this, they require direct access to clinical 
information about individual patients. They make judgments regarding medication use and then 
advocate optimal medication use for individual patients in cooperation with other professionals 
and in consideration of their unique professional knowledge and evaluations. Pharmaceutical 
care includes the active participation of the patient (and designated caregivers such as family 
members) in matters pertinent to medication use” (ASHP, 1993). 
 
The overlaps with the standards and processes that inform ASPs are clear and obvious. This 
study was located within that tradition, and drew upon the theoretical underpinning of the 
concept of pharmaceutical care. The purpose of this retrospective action research was to bring 
forth action and knowledge that will be beneficial to the patients’ health as well the healthcare 
sector in general coupled with contributing to the rational and responsible use of medicines, in 
particular antibiotics, through the application of medicines use evaluation. 
 
2.9 Summary  
CS remains an important risk factor for post-partum infection in many health facilities. As there 
is no consistent protocol for the provision of prophylactic antibiotics for CS in Heidelberg 
Hospital, the findings of this study will help to improve the quality of patient care by using a 
standard protocol for antibiotic prophylaxis as stipulated by the National Department of Health 
or provide evidence for the reconsideration of that protocol. 
 
This chapter comprised of a literature study which covered the key issues pertaining to 
antibiotic prophylaxis in CS. This in turn provided an overall view of important parameters to 
be considered when prophylaxis is administered, taking into account the risk of post-operative 
infections as well as the rising rates of HIV and its association to complications associated with 
CS. It also highlighted the importance of antimicrobial stewardship in facilities and the 
consequences of antibiotic overuse.  
35 
 
CHAPTER III: METHODS 
3.1 Introduction 
Chapter 3 provides an overview of the methods used in the study. It highlights the study design 
used as well as the target population and study sample. It also highlights the methods used in the 
collection of the quantitative and qualitative data, considers the potential for bias and how that 
was managed, and the limitations that were expected and how those were avoided. This chapter 
also describes the ethical approval steps that were required prior to data collection.  
 
3.2 Study design 
A mixed design study was conducted with a quantitative phase as well as a qualitative phase. 
The quantitative phase involved a descriptive observational study design. 
 
3.3 Target population and study sample 
3.3.1 population Target 
The setting for the study was the maternity ward at Heidelberg Hospital, where women 
undergoing Caesarean sections (CS) were treated and where records of their management were 
kept. The population of interest for this study was females undergoing CS deliveries. 
3.3.2 Selection of study population 
The population that was used for the study consisted of patients who were admitted to 
Heidelberg Hospital for CS during a selected 3 month period (April, May, and June 2016) and 
who met the following inclusion criteria:  
• healthy females (adolescents and adults) undergoing CS; and  
• receiving antibiotic prophylaxis associated with CS.  
In addition, data on patients’ HIV status, age and parity was recorded.  
Patients whose records showed vaginal delivery were not considered for the study.  
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3.3.3 Sample size considerations 
For the purpose of this study, a census approach was used. The total number of CS cases 
(elective and non-elective) during the selected 3 month period was estimated to be about 120 
subjects. This was large enough to allow for detailed information about sub-groups within the 
population to be gathered from hospital records. A census approach also avoided sampling bias. 
The method of sampling for the qualitative component, which was aimed at obtaining potential 
reasons for non-compliance from the medical staff, was expert sampling. This was essentially a 
specific sub-case of purposive sampling and was the best way to elicit the views of the medical 
staff that have specific expertise. 
3.4 Collection of interview data (Qualitative phase) 
The qualitative phase involved structured interviews (see Appendix 1) with medical staff to 
establish reasons for any non-compliance which was detected. A total of 7 medical officers were 
approached to participate in the interviews. The medical officers were briefed on the purpose of 
the study, methods used to meet this purpose as well as the benefits of the study and thereafter 
were required to sign an information sheet and informed consent to participate in the research 
(see Appendix 2) before the interview could begin. Individual interviews with an estimated 
length of half an hour were used. Medical officers were asked a series of questions regarding 
their experiences and the use of antibiotic prophylaxis in patients undergoing Caesarean sections 
in the maternity ward at Heidelberg Hospital. Participants were not obliged to answer the 
questions if they felt uncomfortable and were also free to withdraw their consent to participate 
at any time. There was no need for translation since all doctors were fluent in English and used 
this as their preferred language of communication during the interview.   
 
3.5 Collection of exposure data (Quantitative phase) 
A Medicine Use Evaluation data capture sheet (see Appendix 3) was used to extract data from 
the prescriptions and health records for patients who met the inclusion criteria in each of the 
three months under review. Data were recorded on the following elements: 
• demographics (age, ethnicity, parity, HIV status (if known)); 
• reason for the Caesarean section; 
• factors that required treatment with antibiotics post-operatively; 
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• antibiotic name;  
• dose; 
• route of administration; 
• frequency of administration and; 
• duration of treatment. 
Trends in the utilisation of specific antimicrobial medicines, their doses and durations of use 
were established.  
 
The medicines utilisation evaluation (MUE) data collection process was carried out in a series 
of steps: 
 
Step 1: Established responsibility - the Pharmacy and Therapeutics Committee was informed of 
the study as this included members with specific expertise. This step also created a demand for 
the information gathered and improved the chances of implementation of proposed remedial 
actions. 
Step 2: Developed scope of activities - emphasis was placed on the most frequently used 
antimicrobials for surgical prophylaxis and on the cost implications of potential non-
compliance.  
Step 3: Established criteria (guidelines) - defined correct medicines use and thresholds 
according to the appropriate medicine for the target condition, correct dose, duration, 
contraindication, drug-drug interactions and outcome. The criteria were formulated by the 
researcher and thresholds were set as targets,based on value judgements by the researcher. 
Step 4: Collected data through retrospective evaluation - data were extracted from inpatient 
prescription forms and patient records. Due to the absence of electronic databases, data were 
extracted from patient records manually. Average medicine cost was calculated using the cost 
per unit for each antimicrobial given intravenously or orally, using the prevailing tender price as 
charged to the facility by the Gauteng provincial depot. 
Step 5: Analysed data by tabulating results for each indicator and analysed to see if criteria are 
met and threshold was met - attempts to determine why thresholds or benchmarks are not met 
were made, using expert interviews with medical staff.  
Step 6: Developed recommendations to address inappropriate drug use and methods to resolve 
any drug use problem - this is the step where corrective action was implemented after having 
structured interviews with the prescribers so that action was targeted to areas of concern such as 




Step 7: Assessed the effectiveness of the MUE programme - evaluation of the outcomes was 
done and reasons for positive and negative results were documented. Before implementing 
appropriate changes, continued observation will be undertaken. 
 
In order to measure existing practice against a defined standard, the following criteria were 
established, based on the current National Department of Health Standard Treatment 
Guidelines/Essential Medicines List for Adult Hospital care (NDOH, 2012). It was 
acknowledged that these criteria did not represent the locally-developed and implemented 
practices, but the differences were explored in the qualitative phase. The thresholds were set by 




Criteria (Guidelines)  Threshold
 
 Indication  
 Surgical prophylaxis  




       90% 
 Dose   
 Surgical prophylaxis: 1g at induction, repeated 4 hourly 
during prolonged surgery  
 Staphylococci and most Streptococci infections: IM or IV, 
0.5-1g 6-12 hourly; max 6g/day 
 renal impairment : dose adjustment as follows: 
• eGFR* 10-50ml/min, 100% of dose 12 hourly 





       95% 
 Duration  
 Surgical prophylaxis: single dose  
 Staphylococci and most Streptococci infections: 5-7 days 
 
 
       95% 
 Contraindications  
 Previous severe immediate-type hypersensitivity to any 
penicillin or cephalosporin 
 
 
       100% 
 Drug interactions - To be used with caution:  
 Warfarin, NSAIDs, oral contraception, probenecid  
 
 
        90% 
 Outcome  
 No initiation of a therapeutic course of antibiotics post-
delivery 
 Negative cultures 
 No septicemia 
 
        90% 
Table 3.1: MUE Criteria for cefazolin use in surgical prophylaxis in CS 




3.6 Bias and limitations 
The assumption made regarding this study was that it was intended to deliberately change 
prescribing practices among prescribers. It was also difficult to get sufficient time with medical 
practitioners to extract useful information regarding their reasons for non-compliance. Some 
were reluctant to share the reasons for their choices. A non-punitive approach was used, with 
the opportunity to strengthen national guidelines emphasised. Time was a limitation in this 
study; since the data was collected retrospectively, information could only be obtained once CS 
have been done and the time available to extract data was limited. A contributing factor was 
getting approval from the Gauteng Department of Health, which was very time consuming and 
resulted in a delay in the data collection process. Since Heidelberg Hospital is a primary level 
hospital that does not admit a large number of patients, acquiring an adequate sample size was 
yet another limitation.  
 
3.7 Statistical analysis 
At the end of the 3 month period, data were captured from the Medicine Use Evaluation data 
capture sheet onto MS Excel spreadsheets and subjected to descriptive statistical analysis. The 
quantitative data values were represented in a frequency distribution tables by grouping them 
into categories (e.g., age, parity), and thereafter depicted in a frequency distribution bar charts. 
Measures of central tendency were also used (mean, median) as well as measures of dispersion. 
The average treatment cost per patient was calculated and compared to the cost of a single dose 
regimen to highlight the impact on expenditure. 
 
The qualitative data were thematically coded, grouped and then analysed. Thes codes used are 
represented in a table (see Appendix 4). Qualitative data, in the form of interview transcripts, 
were examined for themes that described and explained the reasons for antibiotic prophylaxis 
choices at Heidelberg Hospital. The transcripts were also examined for evidence to justify any 





Prior permission for the study was sought from the clinical manager of Heidelberg Hospital (see 
Appendix 5) as well as conditional approval being granted from the Gauteng Department of 
Health Research Committee (see Appendix 6). Individual patients’ written informed consent for 
the data extraction was not needed, as only anonymised, retrospective data were utilised. 
Nonetheless, final ethical approval was obtained from the Biomedical Research Ethics 
Committee of the Faculty of Health Sciences, University of KwaZulu-Natal (BREC reference 
number: BE508/15) (see Appendix 7). There were no incentives involved for information 
obtained from the medical staff. The study had no sponsors or funding necessary since no 





CHAPTER IV: RESULTS 
4.1 Introduction 
This chapter presents an analysis of the quantitative and qualitative data from the study. All data 
were collected at Heidelberg Hospital and are only representative of the 3 month study period. 
The raw data were extracted from the Medicine Use Evaluation capture sheet and were 
displayed using frequency tables and graphs. Quantitative data such as patient demographic data 
were analysed in terms of descriptive statistics. The gravidity and HIV status of the patients was 
also taken into account. The factors that prompted antibiotic use in post-operative CS patients 
were highlighted in order to examine whether prolonged antibiotic use was justified. The 
indication for the CS performed was also presented as well as the duration of treatment 
received. The qualitative aspect of the study presents data collected through interviews with the 
medical officers and describes their views and opinions regarding antibiotic prophylaxis and 
post-operative management.   
 
4.2 Medicine Use Evaluation 
4.2.1 Patient demographic data 
The records for 120 patients who underwent CS during April, May, and June 2016 were 
examined retrospectively. The patients in the sample had a median age of 26 years (interquartile 
range (IQR): 22-31 years). Most women who delivered fell into the 20-24 and 25-29 years age 
categories as can be seen in Figure 4.1 below. 
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        Figure 4.1: Age distribution of women undergoing CS delivery 
 
4.2.2 Gravidity and HIV status 
Of the 120 patients who delivered by CS, 83 (69.2%) tested negative for HIV. As seen in Table 
4.1, 42 patients (35.0%) were delivering for the first time (Gravida 1), of which the majority (35 
women; 83.3%) were HIV-uninfected. A higher percentage of Gravida 2 patients (15/38, 
39.5%) tested positive for HIV. Of those delivering for the third time (G3), 38.5% (10/26) were 
recorded to be living with HIV. The percentage of HIV-uninfected and HIV-infected women is 










G1 42 (35.0) 35 (83.3) 7 (16.7) 
G2 38 (31.7) 23 (60.5) 15 (39.5) 
G3 26 (21.7) 16 (61.5) 10 (38.5) 
G4 10 (8.3) 6 (60.0) 4 (40) 
G5 1 (0.8) 0 (0) 1 (100) 
G6 2 (1.7) 2 (100) 0 (0) 
G7 1 (0.8) 1 (100) 0 (0) 
TOTAL 120 (100) 83 (69.2) 37 (30.8) 
Table 4.1: Gravidity and HIV status 
The distribution of  gravidity and HIV status is illustrated in Figure 4.2.. 
 
Figure 4.2: Distribution of gravidity and HIV status (N=120) 
 
4.2.3 Indications for Caesarean section 
As CS is not offered on an elective basis in the public sector, the indications for a CS generally 
represent a complication with the pregnancy. Table 4.2 shows the distribution of indications for 
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a CS, stratified by HIV status. As can be seen, in two pregnancies (1 of which was in an HIV-
infected mother), an apparently elective CS was performed. The three most common indications 
for a CS were a prior CS (34/120, 28.3%), foetal distress (27/120, 22.5%) and cephalopelvic 
disproportion (27/120, 22.5%). The percentage of HIV-uninfected and HIV-infected women is 










Previous CS 34 (28.3) 19 (55.9) 15 (44.1) 
Foetal distress 27 (22.5) 19 (70.4) 8 (29.6) 
Cephalopelvic disproportion (CPD) 27 (22.5) 22 (81.5) 5 (18.5) 
Breech position 7 (5.8) 4 (57.1) 3 (42.9) 
Slow progress / prolonged labour 6 (5.0) 3 (50.0) 3 (50.0) 
Foetal distress & cephalopelvic          
disproportion (CPD) 
5 (4.2) 3 (60.0) 2 (40.0) 
Pregnancy-induced hypertension (PIH) 2 (1.7) 2 (100) 0 (0) 
Failed induction 2 (1.7) 2 (100) 0 (0) 
Premature rupture of membranes (PROM) 2 (1.7) 2 (100) 0 (0) 
Twins 2 (1.7) 2 (100) 0 (0) 
Meconium stained liqour (MSL) 2 (1.7) 2 (100) 0 (0) 
Vaginal warts 1 (0.8) 1 (100) 0 (0) 
Grand parity 1 (0.8) 1 (100) 0 (0) 
Apparently elective-no complication 
recorded 
2 (1.7) 1 (50.0) 1 (50.0) 
TOTAL 120 83 (69.2) 37 (30.8) 
Table 4.2: Indications for Caesarean section 
4.2.4 Recorded reasons for extended antibiotic regimens 
Although the NDOH STG recommends that only a single dose of cefazolin be administered, 
pre-operatively, for any pelvic surgery not exceeding 4 hours’ duration, none of the 120 patients 
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received this regimen. Instead, one of two regimens was used during the in-patient stay: 1 day 
of IV cefazolin, administered every 8 hours (83/120, 69.2%) or 3 days’ of IV cefazolin 
administered every 8 hours (37/120, 30.8%). 
It was striking that every HIV-uninfected women (83/120, 69.2%) received 3 doses (1 day) of 
cefazolin IV, whereas every women who was recorded as HIV-infected received 9 doses (3 
days’ therapy) of cefazolin IV and metronidazole IV. As is shown in Table 4.3, this was true 








1 day cefazolin IV 
n (%) 
3 days’ cefazolin IV + 
metronidazole IV 
n (%) 
G1 35 (83.3) 7 (16.7) 35 (83.3) 7 (16.7) 
G2 23 (60.5) 15 (39.5) 23 (60.5) 15 (39.5) 
G3 16 (61.5) 10 (38.5) 16 (61.5) 10 (38.5) 
G4 6 (60.0) 4 (40) 6 (60.0) 4 (40) 
G5 0 (0) 1 (100) 0 (0) 1 (100) 
G6 2 (100) 0 (0) 2 (100) 0 (0) 
G7 1 (100) 0 (0) 1 (100) 0 (0) 
      TOTAL 83 (69.2) 37 (30.8) 83 (69.2) 37 (30.8) 
Table 4.3: Distribution of  gravidity, HIV status and duration of IV antibiotics 
 
Although still in draft form, the widely-distributed Guidelines for Maternity Care in South 
Africa (Department of Health, 2016) have provided a list of conditions where therapeutic rather 
than prophylactic antibiotics are indicated:  
• severe immunocompromise (e.g. history of recent AIDS defining illness or CD4+ cell 
count<250 cells/mL); 
• evidence of chorioamnionitis (including offensive liquor); 
• prolonged labour with many per vaginal examinations after rupture of membranes; 
• obstructed labour (usually with systemic signs of sepsis); and 
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• CS delivery following failed vacuum extraction 
 
Once this draft became available, an attempt was made to track whether the clinical notes 
indicated application of these principles. However, for 11/120 cases (9.2%), the original notes 
could not be retrieved again. However, in every case, previous data extraction had recorded HIV 
status and the duration of IV antibiotics. As shown in Table 4.4, 102/120 patients (85.0%) did 
not have a reason from this list recorded as justification for a full therapeutic course rather than 
a prophylactic course. However, the link between HIV status and duration remained as 
invariable as before. In each of the 7/120 (5.8%) cases in which a discernible cause for the 
prolonged antibiotic course was recorded, this was based on prolonged labour with many per 
vaginal examinations after rupture of membranes. Nonetheless, 6/7 of these patients received 
only 3 doses of cefazolin IV. Only one patient was readmitted during the study period for sepsis 
and was treated accordingly with antibiotics. As shown in Table 4.4, in addition to the IV 
cefazolin administered in the ward, each HIV-infected patient also received metronidazole 















IV  n (%) 
3 days’cefazolin IV 
+ metronidazole IV 
           n (%) 
 
Present 7 (5.8) 6 (85.7) 1 (14.3) 6 (85.7) 1 (14.3)  
Absent 102 (85.0) 71 (69.6) 31 (30.4) 71 (69.6) 31 (30.4)  
File not 
found 
11 (9.2) 6 (54.5) 5 (45.5) 6 (54.5) 5 (45.5)  
TOTAL 120 83 (69.2) 37 (30.8) 83 (69.2) 37 (30.8)  
Table 4.4: Factors requiring prolonged (therapeutic) antibiotics 
 
As seen in Figures 4.3 and 4.4 below, the duration of treatment in the presence or absence of 
factors requiring antibiotics corresponded only with the HIV status of the patients, and not with 





Figure 4.3: Distribution of patients and duration of treatment received, by presence or 
absence of discernible indications for prolonged antibiotics (N=109) 
 
 
Figure 4.4: Distribution of HIV status and presence or absence of discernible indications 





When the indications for CS were compared with the recorded reasons for CS, some of which 
also included reasons that overlapped with those stipulated in the draft Guidelines for Maternity 
Care in South Africa (Department of Health, 2016) for a therapeutic rather than prophylactic 
course of antibiotics, the connection with regard to HIV status and treatment was maintained, 



















Previous CS 19 (55.9) 15 (44.1) 19 (55.9) 15 (44.1) 
Foetal distress 19 (70.4) 8 (29.6) 19 (70.4) 8 (29.6) 
Cephalopelvic  disproportion (CPD) 22 (81.5) 5 (18.5) 22 (81.5) 5 (18.5) 
Breech position 4 (57.1) 3 (42.9) 4 (57.1) 3 (42.9) 
Slow progress / prolonged labour 3 (50.0) 3 (50.0) 3 (50.0) 3 (50.0) 
Foetal distress & cephalopelvic 
disproportion (CPD) 
3 (60.0) 2 (40.0) 3 (60.0) 2 (40.0) 
Pregnancy-induced hypertension (PIH) 2 (100) 0 (0) 2 (100) 0 (0) 
Failed induction 2 (100) 0 (0) 2 (100) 0 (0) 
Premature rupture of membranes 
(PROM) 
2 (100) 0 (0) 2 (100) 0 (0) 
Twins 2 (100) 0 (0) 2 (100) 0 (0) 
Meconium stained liqour (MSL) 2 (100) 0 (0) 2 (100) 0 (0) 
Vaginal warts 1 (100) 0 (0) 1 (100) 0 (0) 
Grand parity 














TOTAL 83 37 83 37 
Table 4.5: Indications for Caesarean sections and duration of treatment 
As shown in Table 4.5, a combination of medicines was administered for HIV-infected patients.  
Then, regardless of HIV status, every patient was issued on discharge with a prescription for 
oral amoxicillin 500mg 15 (500mg every 8 hours for 5 days) and oral metronidazole 400mg 21 
52 
 
(400mg every 8 hours for 5 days). Those who were HIV-negative therefore received at least 6 
days of continuous antibiotics, and those who were HIV-positive received at least 8 days of 
continuous antibiotics, in each case a combination of a beta-lactam and metronidazole 
(presumably to cover anaerobic bacteria). Each of these would constitute a therapeutic course 




Criteria (Guidelines) Threshold Score 
 
 Indication  
 Surgical prophylaxis  






 Dose   
 Surgical prophylaxis: 1g at induction, repeated 
4hourly during prolonged surgery  
 Staphylococci and most Streptococci infections: 
IM or IV, 0.5-1g 6-12 hourly; max 6g/day 
 renal impairment : dose adjustment as follows: 
• eGFR 10-50ml/min, 100% of dose 12 
hourly 







 Duration  
 Surgical prophylaxis: single dose  







 Contraindications  
 Previous severe immediate-type hypersensitivity 






 Drug interactions - To be used with caution:  






 Outcome  
 No initiation of a therapeutic course of antibiotics 
post-delivery 
 Negative cultures 





Table 4.6: MUE criteria for cefazolin use as applied to actual practice 
4.2.5 Compliance to guidelines 
A predetermined set of criteria with threshold values was set to measure the level of compliance 
to the STG. According to the results presented in Table 4.6 above, there was 100% compliance 
with regard to the indication and dose for which cefazolin was used. However, every case the 
correct duration was not prescribed. Patients were administered more than one dose of 
cefazolin, hence a compliance score of 0% for that particular criterion was recorded. Another 
particular criterion in which a 0% score was recorded was the prescription of therapeutic 
antibiotics post-delivery. Overall, the review indicated that there was non-compliance to the 
guidelines presented in the STG. 
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4.2.6 Cost analysis 
The total and average medicine cost was calculated as per the cost per unit for each 
antimicrobial given intravenously and orally, using the prevailing tender price as charged to the 
facility by the Gauteng provincial depot. Only the direct medicine cost was taken into 
consideration, and not the cost of administration. The current unit cost prices at the time of the 
study were: 
• Cefazolin 1g vial: R4.43 
• Metronidazole 500mg vial: R6.13 ` 
• Amoxicillin 500mg capsules 15s: R7.87 
• Metronidazole 400mg tablets 21s: R4.76 
The total and average medicine cost was calculated for the study period (April, May and June 
2016) for all patients who received antibiotics in the ward post-operatively and after discharge. 
This was inclusive of all intravenous antibiotics received (whether 1 or 3 day courses) and post-
discharge oral antibiotics. As no stock shortages were experienced during the study period, all 
patients received the same medicines, as prescribed. It was found that the total cost of 
intravenous antibiotics for HIV-uninfected patients amounted to R1103.07, with a mean of 
R13.29 per patient. The total cost for HIV-infected patients was R3516.48, with a mean of 
R95.04 per patient. The cost for each HIV-infected patient was therefore more than seven times 
the cost for an HIV-uninfected patient. The total cost for post-discharge antibiotics amounted to 
R1515.60 with an average of R12.63 per patient. When combined, the total costs for all HIV-
infected were R3983.79 (mean R107.67 per patient) and for HIV-uninfected R2151.36 (mean 
R25.92 per patient), as shown in Figure 4.5. A total of R5603.55 would have been saved had 
every patient received the stat dose as stipulated in the national guidelines, R103.24 saved per 















4.3 Qualitative data  
Only 7 medical officers were available to participate in the interviews. The majority of non-
respondents indicated that they were busy or did not perform CS often enough to provide 
meaningful comment. Heidelberg Hospital has a small maternity ward, hence only a limited 
number of medical officers perform CS on a regular basis. Informed consent was obtained from 
all medical officers prior to participation and confidentiality was assured. Responses were 
recorded verbatim. The data were themed according to their responses and entered into 





Negative experiences regarding post-Caesarean section infections 
 
Common  0 (0) 
Rare 7 (100) 
   
Personal experiences have affected prescribing practices in relation to 
antibiotic prophylaxis in CS 
 
Yes 3 (42.9) 
No 4 (57.1) 
   
There is a protocol in place for the administration of antibiotic 
prophylaxis in patients undergoing CS 
 
Yes 5 (71.4) 
No 1 (14.3) 
Unsure  1 (14.3) 
   
Prescriber is personally familiar with the antibiotic prophylaxis 
recommendations included in the National Department of Health 
Standard Treatment Guidelines 
 
Yes 4 (57.1) 
No 3 (42.9) 
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Details of the pre- and post-operative antibiotic prophylaxis regimen 
used in CS 
 
Pre-op:   Cefazolin 1g IVI   
Post-op: Cefazolin 7 (100) 
Post-discharge: Amoxicillin & Metronidazole 
 
 
Doses prescribed and duration  
Pre-op:       1g     < 60 minutes before the first incision  
Post-op:      1g    8 hourly IVI  over 24 hour period (3 Doses)   
Post-discharge:  7 (100) 
Amoxicillin 500mg  8 hourly P.O over a 5 day period  
Metronidazole  400mg 8 hourly P.O over a 5 day period 
 
 
Specific reasons for the  regimen and duration exist  
Yes 4 (57.1) 
No 3 (42.9) 
   
Doses used for HIV-positive patients  
Pre-op:   Cefazolin 1g IVI < 60 minutes before the first incision  
Post-op: Cefazolin 1g every 8 hours IVI for 3 days (9 doses)  
                Metronidazole 500mg every 8 hours IVI for 3 days (9 doses) 7 (100) 
Post-discharge: Amoxicillin 500mg every 8 hours P.O for 5 days  
                          Metronidazole  400mg every 8 hours P.O for 5 days  
Feelings about having to follow a different prophylactic regimen from 
that stated in the NDOH STG 
 
 




Not willing since there is no problems with the current regimen 1 (14.3) 




Need for changes in the NDOH STG regarding CS antibiotic prophylaxis 
Yes 7 (100) 
No 0 (0) 
Table 4.7: Frequency table depicting themed codes for responses 
 
All medical officers reported that, in their own experience, post-CS infections at Heidelberg 
Hospital were rare. Respondent 4 made a subtle change to that response, though, claiming that 
post-CS infections were: 
“not common however infections seem to be higher in summer, ecological factors 
play a role and common in obese people.” 
According to respondent 6, rates of infection were: 
“very low, post CS infections are often related to the indication of CS, the nature of 
labour and immunological state” 
 
Despite acknowledging that their personal experiences of post-CS sepsis were rare, 3/7 
respondents (42.9%) felt that their personal experiences in the past had affected their prescribing 
practices in relation to antibiotic prophylaxis in CS. Respondent 1 felt that factors to be borne in 
mind included: 
“a rarely fumigated theatre and a lot of immunocompromised patients” 
Respondent 3 said that it was important to: 
“judge the situation as other bacteria is present, Kefzol covers a broader 
spectrum.” 
Respondent 4 felt that the: 
“outcome is different depending on cases eg, malnutrition, prolonged labour, 
immunocompromised patients especially in HIV-positive patients.”  
On the other hand, respondent 2 felt that prescribing practices would differ in the case of 
established sepsis: 
“if there is an infection in the ward then stay will be extended to 5 days.” 
Respondent 6 indicated that prescribing choices were not affected by specific patient 
factors, such as patient body mass: 
“prophylaxis is standard even for obese patients.”.  
 
The majority of the respondents (5/7, 71.4%) was aware that there was a hospital-specific 
protocol in place for the administration of antibiotic prophylaxis in patients undergoing CS. 
Interestingly, though, respondent 2 indicated that there was no particular protocol in place as: 
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“this is the hospital practice and they follow recommendations from the morbidity 
and mortality meetings.” 
 
Almost half (3/7, 42.9%) could provide no specific reasons for following the existing protocol, 
beyond that it was hospital policy. Others did provide reasons, including: 
“Kefzol is a 1st grade (sic)cephalosporin and it is good if it is an invasive surgical 
procedure, to reduce chances of resistance and in case of poor response there is a 
lot of other antibiotics available.” (Respondent 1) 
“Has an extended spectrum and HIV-positive patients are more susceptible to 
infections.” (Respondent 2) 
“Kefzol has a broad spectrum cover for most surgical procedure.” (Respondent 3) 
“A smaller theatre is being currently used, dangerous practices as is not as 
hygienic, this regimen is standard and common in most hospitals so its hospital 
policy. Patient treatment is individualised.”(Respondent 4) 
 
Just over half of the respondents (4/7, 57.1%) were familiar with the antibiotic prophylaxis 
recommendations included in the National Department of Health Standard Treatment 
Guidelines.  
 
Despite knowing about the NDOH STG, there was unanimous agreement that HIV-positive 
patients should receive intravenous antibiotics for 3 days (9 doses), by virtue of their being 
immunocompromised. Respondent 2 added that the: 
“CD4 count is not always available so Flagyl is added to extend the spectrum of 
antibiotic activity since patients are immunocompromised.” 
 
In terms of their feelings about having to follow a different prophylactic regimen from that 
stated in the NDOH STGs, almost all respondents (6/7, 85.7%) were willing to follow new 
recommendations, provided they were evidence-based. Respondent 4 suggested that: 
“resistance and ecological changes should be taken into account and more money 
should be invested in investigating alternative regimens.”  
Only one respondent (respondent 5) was not willing to change practice, as he felt that there were 
no problems with the current recommendations in the STG and stated: 




All 7 medical officers had suggestions for changes or recommendations for consideration in the 
Standard Treatment Guidelines regarding antibiotic prophylaxis in CS, as follows: 
 
“Conduct studies to see trends of infections in immunocompromised patients and 
those with stronger immunity and conduct studies to find common pathogens that 
are the culprit for sepsis in the area before changes are made.” (Respondent 1) 
“HIV positive patients should be considered, extend 1g Kefzol to 3 more doses in 
the STG.” (Respondent 2) 
“STG needs to provide more information, STG should be specific for district and 
tertiary levels, consider other antibiotics by identifying common bacteria that 
causes sepsis, Kefzol is cheap and effective and comfortable with it.” (Respondent 
3) 
“To avoid confusion let doctors know that the MCG is available, STG needs more 
improvement and more information with regard to maternal care, a part of 
Millennium Development Goals was to improve maternal care therefore the MCGi 
and STG should be consolidated.” (Respondent 4) 
“There is no need for post op antibiotics if there are no complications with the 
exception of HIV positive patients.” (Respondent 5) 
“STG does not take into account the patient and should be more patient-centred, 
there are different schools of medicine therefore there is a need for more 
consolidated and unified information.” (Respondent 6) 
“Add more broad spectrum antibiotics, consider Augmentin (a penicillin) for 




Both quantitative and qualitative data showed that antibiotic prophylaxis practice after CS at 
Heidelberg Hospital did not follow the NDOH STG, but consistently followed a local hospital 
policy, supposedly based on local experiences, and specifically aimed at providing a greater 
degree of protection to patients identified as HIV-positive and hence assumed to be 
immunocompromised. In addition to extended courses of IV antibiotics (either 3 or 9 doses, 
                                                 
iMCG refers to the Maternal Care Guidelines 
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including IV metronidazole in the latter cases, as opposed to the single dose cefazolin 
prescribed in the STG), all patients who underwent a CS delivery were discharged with an 
additional 5 days’ of oral antibiotics. 
 
The implications of these finding are considered in Chapter V. 
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CHAPTER V: DISCUSSION 
5.1 Introduction 
The purpose of this chapter is to elaborate on the results provided in Chapter 4 and to place 
these in the context of the available literature. This chapter highlights the interpretation of the 
quantitative and qualitative results. It looks at the extent of non-compliance with national 
guidelines and provides possible reasons for such non-compliance. 
 
5.2 Medicine Use Evaluation 
5.2.1 Reasons for CS and choice of prophylactic regimen 
Studies have indicated that, as parity increases, so does the incidence of haemostatic problems 
(Moodliar et al., 2007). HIV status was applied, regardless of gravidity or age, to decide 
whether women received 3 or 9 doses of intravenous antibiotics. In addition, those on the 3-day 
course also received IV metronidazole, and all patients were discharged with an additional 5 
days’ of oral antibiotics. This was in direct contradiction of the existing NDOH guidance, which 
called for a single dose of IV cefazolin, within an hour of the first incision.  
 
In the current study the complications which prompted a CS were seen among all age groups. 
However, as expected, the incidence of infectious complications post-CS was very limited, so a 
connection cannot be made between age, parity or HIV status and complications.   
 
The recorded indication for a CS also did not correlate with the duration of prophylactic 
antibiotics. The most prevalent indication for a CS was a previous CS, accounting for 28.3% of 
cases. This finding is consistent with the literature. The next most prevalent indication, 
regardless of HIV status, was CPD (22.5%) and foetal distress (22.5%). In a study conducted by 
Gidiri and Ziruma (2014) in Zimbabwe, the most prevalent indication for CS was also a 
previous CS, followed by foetal distress and CPD. 
 
Similar findings were reported by Naidoo and Moodley (2009), who contrasted the foetal 
distress rates in South Africa and the UK. Conservative measures should be considered before a 
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decision is made to perform a CS and failure to progress maybe one indication to consider. The 
authors also suggested that CPD should be excluded by conducting skilled pelvic examination 
and that careful utilisation of oxytocin to augment labour may help to avoid unnecessary CS 
without affecting foetal outcomes. Nonetheless, inexperienced medical officers may be hesitant 
to resort to such measures as they fear litigation and will have to provide intense foetal and 
maternal monitoring to prevent uterine hyperstimulation and subsequent foetal distress. 
 
According to the available literature, patients living with HIV have a higher risk of 
complications. However, in the current study, patients reported to be HIV-negative were shown 
to have a higher rate of complications requiring CS. The number of such cases was, however 
limited, and the result may be an effect of chance. Patients’ HIV status did not appear to play a 
direct role in terms of complications, but was directly and invariably responsible for the 
duration of antibiotic use. Evidence from the literature, and in particular from the systematic 
review conducted by Calvert and Ronsmans (2013), suggest that the risk of intrauterine 
infections during pregnancy, delivery or the post-partum is increased due to HIV. Women living 
with HIV who delivered vaginally or through CS were shown to have over three times the risk 
of puerperal sepsis when compared with uninfected women. However, the degree of 
immunosuppression is important. Ferrero and Bentivoglio (2003) showed that the incidence of 
complications was significantly increased in HIV-positive mothers when their CD4 
lymphocytes count fell below 500x106/l. Unfortunately, in the current study the patients’ viral 
load and CD4 cell count was not available at the time of admission. A rapid HIV test was done 
to check HIV status, but the degree of immunosuppression was not considered. As much of the 
pregnancy-related mortality seen in women living with HIV is not likely to be a result of direct 
obstetric complications, it is crucially important that high quality antenatal and delivery services 
are provided to all pregnant women, and that timeous initiation of antiretroviral therapy (ART) 
is achieved in those living with HIV. Thus, while there is a theoretical benefit from the 
provision of prophylactic antibiotics to women living with HIV undergoing CS, in order to 
reduce their risk of intrauterine infections, the blanket provision of 3 days’ prophylaxis is 
questionable. The 8 days’ course provided can only be characterised as an unnecessary 




5.2.2 Reasons for extended antibiotic regimens 
Over 3 decades, researchers have reported that almost 50% of antibiotics used in hospitals are 
used inappropriately (Goldmann et al., 1996). Despite this, not much has been achieved to 
reduce costs and the selection pressure for drug-resistant bacteria. The misuse of antibiotics in 
CS has become a particular problem at Heidelberg Hospital. As seen in this study, 85% of 
patients did not have a particular reason to receive extended post-operative antibiotics in an 
attempt to prevent SSIs. The treatment was nevertheless entirely compliant with a local practice 
standard, and consistently based on the patients’ HIV status.  
 
Dhar et al. (2014) have shown that prolonged labour with frequent vaginal examinations and 
PROM may contribute to increased infection rates in such cases. In addition, the length of time 
between the rupture of the membranes and surgical intervention contributes to the infection rate 
post-CS (Gould, 2007). The small number of patients (5.8%) in this study who might have been 
considered to deserve a full therapeutic course of antibiotics, because of an identified 
complication, still received a course determined by their HIV status. In 85.7% of these 
supposedly complicated cases, the patient was HIV-uninfected, and therefore received only 3 
doses of IV cefazolin. If the reason for their complicated status is accepted as justifying a full 
therapeutic course, as guided by the draft Maternity Care Guidelines (Department of Health, 
2016) they might be considered to be under-treated. However, even when only a single day of 
IV antibiotics was prescribed, all patients, regardless of HIV status or diagnosed complications, 
were discharged with an additional 5 days’ of oral antibiotics. 
 
The findings of this study were important, given the increasing rates of CS in South Africa. 
Mugford et al. (1989) have highlighted that reducing the number of avoidable CS will help 
reduce the infection rate post-CS. In the current study, only 1.7% of CS were performed 
electively, without any documentation of a complication requiring a CS. Mugford et al. (1989) 
also emphasised the need to practise and maintain good sterile surgical techniques, in a suitably 
sterile operating theatre. In this regard it is worth noting that the Heidelberg Hospital theatre is a 
temporary structure, currently being used after the previous theatre was damaged in a fire. The 
air quality and sterility of the theatre may therefore not meet all requirements. 
 
The development of SSIs can be a very daunting experience for a clinician. Wound infections in 
patients who had surgeries are still observed to be the most common nosocomial infections 
(Smyth and Emmerson, 2000). In the current study only one case of post-CS sepsis was reported 
in the 3 month study period. 
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Apart from post-CS SSIs contributing to maternal morbidity, they also prolong the duration of 
hospital stay, further increasing costs. In a study by Dhar et al. (2014), women who had CS 
deliveries were normally discharged on the third post-operative day. However, this stay was 
extended to an average of 5-8 days should a woman develop an SSI in the hospital. At 
Heidelberg Hospital, HIV-positive patients were generally discharged after the third day and 
only kept longer in the event of an infection (Dhar et al., 2014). However, the initial extension 
in the length of stay could be directly related to the prescription of 3 days’ of IV antibiotics. 
 
5.2.3 Compliance with national standard treatment guidelines 
The results from the MUE confirmed the level of non-compliance with the NDOH STG. The 
indication for which cefazolin was being used was appropriate, as it was administered for 
surgical prophylaxis. The dose of 1g initially prescribed was in accordance with the STG. 
However there was 0% compliance in respect of the duration of treatment. Since the duration of 
the procedure was always less than 60 minutes, a single dose would have sufficed. However, in 
all cases, multiple doses were given post-operatively. There was also 0% compliance in the 
outcome, as therapeutic courses of antibiotics had been initiated. 
 
5.2.4 Cost analysis 
There was a considerable difference in the costs for HIV-negative and HIV-positive patients. 
The cost of IV antibiotics for HIV-positive patients was more than seven times higher than that 
for HIV-negative patients. The impact on the pharmacy budget would therefore have been 
considerable, with little or no justification. A similar practice was also documented in a study by 
Gidiri and Ziruma (2014), in which patients were given intravenous treatment in addition to a 
standardised course of antibiotics for a week; and received amoxicillin 500mg three times a day 
for 7 days, metronidazole 400mg three times a day for 7 days from the first post-operative day. 
This practice was thus similar to what was shown at Heidelberg Hospital. Gidiri and Ziruma 
(2014) found no statistically significant difference in patients who received a single (stat) dose 
of antibiotic prophylaxis compared to those who received treatment for a week. The available 
literature also provides convincing evidence that a single dose of antibiotics is effective in 
preventing post-surgical wound infections (Hedrick and Sawyer, 2012). The existing NDOH 
policy of routine prophylaxis with a single dose of an IV antibiotic such as cefazolin would be 
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expected to be effective in preventing SSIs post-operatively, and therefore be cost effective. The 
chances of poor adherence to the post-discharge oral antibiotics might be high, also contributing 
to fruitless expenditure. In addition, the chances of adverse effects to antibiotics are raised with 
extended courses, potentially adding further avoidable costs (Mugford et al., 1989).  
 
Despite local medical practitioners having knowledge of the existing NDOH guidelines, they 
have developed local standards of practice which entrench prolonged use of antibiotics. This 
inevitably places added pressure on nurses by increasing the workload in an already 
understaffed hospital, increasing the costs to patients as well as the healthcare system. 
 
5.3 Qualitative data  
The quantitative results from the MUE showed a high level of non-compliance with the NDOH 
STGs. The qualitative portion of the study sought to uncover possible reasons for this non-
compliance, based on the perceptions and fears of the local medical practitioners and their 
expressed logical basis for their prescribing patterns. Heidelberg Hospital is a district hospital 
with a limited number of medical officers who perform CS. Hence not all the medical officers 
are familiar with current practices regarding antibiotic prophylaxis, which is explained by the 
small number of respondents. A lack of time to engage with the study also hampered 
achievement of a higher response rate. 
 
According to the interview data, local medical officers regarded post-CS infections as very rare 
at Heidelberg Hospital. During the 3 month study period, which was all in the winter months, 
only 1 patient was readmitted for sepsis after a CS. Despite this rarity, the clinicians were of the 
opinion that there were discernible risk factors. For example, Respondent 4 claimed that 
“infections seem to be higher in summer” and that “ecological factors play a role”. 
 
Although 57.1% of the respondents stated that their own personal experiences had not affected 
their prescribing practices, the majority were comfortable to follow the standard hospital policy, 
contrary to the NDOH STG. In terms of the local standard, prolonged therapeutic courses were 
not based on identified or suspected sepsis, but purely on the basis of HIV status. Respondent 6 
noted the lack of individualised care, for example that “prophylaxis is standard even for obese 
patients”. It is notable that the literature supports the concern that obese patients are at higher 
risk of developing infections (Wloch et al., 2012). The current NDOH STG does not allow for 
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adjustment of prophylactic doses in obese patients, even though this may be warranted on the 
basis of pharmacokinetic considerations. 
 
Although only 71.4% of respondents stated that they were aware of the hospital protocol 
regarding prophylaxis, the majority claimed to be following “hospital policy”. Only 57.1% 
were familiar with the recommendations stated in the NDOH STGs. Interestingly, Respondent 2 
indicated that there was no particular protocol in place, but that “this is the hospital practice 
and they follow recommendations from the morbidity and mortality meetings.”After the 
researcher asked to see the protocol, no written document could be produced. Nonetheless, the 
MUE demonstrated the consistent application of a local policy on antibiotic prophylaxis in CS. 
In such a setting, newly appointed and inexperienced medical officers will tend to follow the 
practices of more senior staff, or their peers, regardless of the existence of the NDOH STGs. A 
majority of the respondents (57.1%) claimed to have specific reasons for following the local 
regimen. The remainder (42.9%) seemed to be comfortable merely following what they were 
told was hospital policy. Among the reasons cited was that “Kefzol is a 1st grade (sic) 
cephalosporin and it is good if it is an invasive surgical procedure, to reduce chances of 
resistance and in case of poor response there is a lot of other antibiotics available.”Although 
the choice of a first-generation cephalosporin is appropriate, this does not explain the extended 
duration, the addition of metronidazole in the 3-day regimen, or the decision to add a full 5-day 
course of post-discharge oral antibiotics. It was claimed that “this regimen is standard and 
common in most hospitals so its hospital policy”. The claim that “patient treatment is 
individualised” in the event of an infection would appear to describe standard practice, but 
could not be confirmed with any certainty from the sample drawn. While it is true that there are 
“a lot of other antibiotics available”, that does not excuse putting the first-line prophylactic 
choice at risk by overuse, potentially increasing the risk of selecting resistant hospital 
organisms. 
 
An element that could not be as easily dismissed was the concern about the standard of the 
facilities being used. Respondent 4 indicated that “[a] smaller theatre is being currently used”, 
and that “dangerous practices” were being followed, and that the facility “is not as hygienic”. 
Unfortunately, Heidelberg Hospital’s operating theatre does not currently allow for the practice 
of appropriate aseptic techniques as the theatre is still under reconstruction. The WHO requires 
the maintenance of a proper ventilation system in operating theatres, with around 20 air changes 




With regard to the pre-and post-operative antibiotic regimen used, although this did not strictly 
constitute “prophylaxis”, all the respondents held that this was an appropriate regimen. A 
similar regimen was reported by Gidiri and Ziruma (2014) in Zimbabwe, where it was standard 
practice to administer an extended course of antibiotics, even in the absence of an established or 
suspected infection. 
 
All of the respondents stated their support for the extended regimen used in women living with 
HIV, and justified this by reference to the “immunocompromised” state of the patients. 
Respondent 2 added that the “CD4 count is not always available so Flagyl is added to extend 
the spectrum of antibiotic activity since patients are immunocompromised.”While it is true that 
studies have reported that HIV-infected women who give birth by CS have a considerably 
increased incidence of complications (Semprini et al., 1995), this heightened risk is correlated 
with the extent of immune compromise (Moodliar et al., 2007). Although the numbers were 
small, the current study did not appear to confirm an increased risk of post-CS infection in 
women living with HIV. However, none of the clinical notes provided evidence of either viral 
load or CD4 measurements. The blanket administration of 9 doses of combined IV antibiotics, 
followed by 5 more days’ of oral antibiotics can therefore not be justified. Since the NDOH has 
now mandated a test-and-treat approach to patients living with HIV, including pregnant women, 
there should be no delay in initiating ART. Although CD4 counts have been relied upon in the 
past, a better measure of the degree of control achieved through ART would be a viral load, 
taken before CS. However, the practicality of such a policy in a district hospital might still be 
questioned. In the event of an unknown viral load, the question still remains whether an 
extended duration of prophylaxis is needed, in the absence of complications that might indicate 
the need for a full therapeutic course. 
 
The 2015 draft “Guidelines for Maternity Care in South Africa - A manual for clinics, 
community health centres and district hospitals” (Department of Health, 2015) state that 
“Caesarean section is associated with an increased risk of maternal infection, haemorrhage, 
thromboembolism, postpartum death, and obstetric complications in subsequent pregnancies. 
Women who ask for Caesarean section and have no clinical indication for the operation should 
be counselled about the risks and benefits of the procedure.” They mandated that “[j]ust before 
starting the operation, ensure that: …..[a] broad-spectrum prophylactic intravenous antibiotic is 
given, e.g. cefazolin 1 g, irrespective of whether the operation is an emergency or elective 
procedure.” (pg 55) However, three later mentions give conflicting advice, as follows: (pg 56): 
“Prescribe additional (therapeutic) doses of antibiotics for 24 hours to 5 days in women who 
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have risk factors for infection, (e.g. all HIV infected women; prolonged labour or prolonged 
ruptured membranes; Caesarean section in second stage labour, chorioamnionitis, >5 vaginal 
examinations during labour, when the fetal head needed to be pushed up vaginally); pg (139): 
“Prophylactic antibiotics are given for both elective and emergency Caesarean section: 
Cefazolin 1 g IVI when on the operating table prior to the start of surgery, followed by a broad-
spectrum antibiotic for 3-5 days”; and (pg164): “Women with risk factors for infection (HIV 
infection, prolonged labour, prolonged rupture of membranes, chorioamnionitis, or Caesarean 
section in the second stage) may need to be kept in hospital on antibiotics for 3-5 days.” 
However, the 2016 (current) draft (Department of Health, 2016) has altered this advice 
somewhat: (pg 47): “Just before starting the operation, ensure that: …..Broad-spectrum 
intravenous antibiotics have been given. These may be either prophylactic or therapeutic 
antibiotics. Routinely, a dose of prophylactic antibiotics (e.g. cefazolin 1g) is given pre-op, 
irrespective of whether the operation is an emergency or elective procedure, and there is no need 
to give further doses of antibiotics post-op. If, however, the patient has evidence of intra-uterine 
sepsis, or there are factors which put her at high risk of post-operative sepsis, then intravenous 
therapeutic antibiotics (e.g co-amoxyclav 1.2g) should be started pre-op and continued post-op 
for five days, although intravenous antibiotics could be changed to oral antibiotics after a few 
days depending on the patient’s condition.” The guidelines further state that: “Indications for 
therapeutic rather than prophylactic antibiotics include: 
• severe immunocompromise (e.g. history of recent AIDS defining illness or CD4 <250) 
• evidence of chorioamnionitis (including offensive liquor) 
• prolonged labour with many per vaginal examinations after rupture of  membranes 
• obstructed labour (will usually have systemic signs of sepsis) 
• Caesarean delivery following failed vacuum extraction.” 
 
A subtle change in thinking is evident in this progression in the guidelines from the 2015 to the 
2016 drafts, but the guidance is still at variance with the NDOH STGs, and that conflict has yet 
to be resolved. The concern with avoiding all post-operative maternal sepsis by any means is at 
loggerheads with the need to conserve antimicrobials through restricting unnecessary use. 
 
It was striking that 85.7% of the respondents were willing to follow new recommendations 
provided they relied on evidence-based research. Only one respondent (14.3%) was satisfied 
with the current recommendation provided in the STG, and felt that it did not need to be 
changed: “if it is working there is no need to change it unless the rate of sepsis increases.” The 
onus would, however, seem to be on those who wish to change the existing STG, which is based 
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on global evidence, rather than on the National Essential Medicines List Committee (NEMLC) 
to justify their guideline. The drafters of the Guidelines for Maternity Care in South Africa also 
need to provide clear evidence to justify full therapeutic courses of antibiotics in each of the 
circumstances listed in the 2016 draft document, if these are to supersede the STGs (and force a 
change in the latter document). 
 
Notably, every respondent had suggestions for consideration by the NEMLC, and were of the 
opinion that the current STG had insufficient information with regard to maternal health and 
antibiotic prophylaxis for CS (as opposed to all pelvic surgery) and that there was a need for a 
more “consolidated and unified guide”. Suggestions for making the guidance “more patient-
centred” and considering HIV-positive patients were put forward. This would appear to be a 
reasonable request as the current STG does not take into account such factors as body mass or 
immune dysfunction.  
 
Respondent 1 suggested that studies be conducted “to see trends of infections in 
immunocompromised patients and those with stronger immunity and conduct studies to find 
common pathogens that are the culprit for sepsis in the area before changes are made.” 
Respondent 2 indicated that “HIV positive patients should be considered” and suggested that 
the guidelines “extend 1g Kefzol to 3 more doses in the STG”. Respondent 3 also suggested that 
there was a need to “consider other antibiotics by identifying common bacteria that causes 
sepsis”. Respondent 5 was content with the current guidance for a stat dose, but indicated that 
“[t]here is no need for post op antibiotics if there are no complications with the exception of 
HIV-positive patients”. Respondent 7 indicated that “more broad spectrum antibiotics” should 
be added, and suggested “Augmentin (a penicillin) for prophylaxis”. As discussed in chapter II, 
the choice of a first-generation cephalosporin such as cefazolin has broad support. Whether 
additional epidemiological studies are necessary to track local causative organisms and their 
sensitivity patterns is therefore open to question. However, given the prominence of HIV as a 
contributing factor to excessive maternal morbidity and mortality, some consideration of the 






5.4 Appropriate remedial actions identified  
The results of this study provide clear evidence of non-compliance with existing STGs. 
Although local Drug and Therapeutics Committees are empowered to consider the need for 
local policies, in the absence of clear evidence for a change, the issue of prophylactic regimens 
in CS needs to be decided at higher levels, at provincial and national level. There would seem to 
be sufficient evidence for reconsideration of the local hospital protocol, as it does not appear to 
be evidence-based and is evidently contributing to increased workload and costs.  
 
 
5.5 The need to review the NDOH STG 
Insufficient evidence has been provided by the current study to motivate for changes to be made 
to the regimen for antibiotic prophylaxis in CS stipulated in the current NDOH STG. The 
administration of a single dose of cefazolin IV before commencing a CS is consistent with and 
supported by the recently launched WHO guidelines on preventing surgical site infections, 
published on 3 November 2016. The WHO strongly recommends that surgical antibiotic 
prophylaxis be administered within 120 minutes prior to the first incision also taking in to 
account the half-life of the antibiotic. In order for the antibiotic to provide a protective effect, 
the antibiotic should be present in the affected tissues at an adequate concentration at the time of 
incision and during the procedure. For this reason antibiotics should be administered before the 
incision. WHO also recommended that administration of antibiotics with a short half-life (such 
as cefazolin, cefoxitin and penicillins in general) should be done closer to the time of incision 
(less than 60minutes as stated in the current STG) so that the protective effect will persist. 
Several other guidelines, such as those published by the ASHP (Bratzler et al., 2013) and 
SHEA/ IDSA (Anderson et al., 2014), support the administration of prophylaxis within 60 
minutes prior to incision and recommend its discontinuation within 24 hours post-operatively. It 
is very important to note that WHO strongly recommended against the prolongation of surgical 
antibiotic prophylaxis (SAP) being administered post-operatively for the purpose of preventing 
SSI. Based on the available evidence, and also taking into account the possible adverse events 
and potential risk of the emergence of antimicrobial resistance associated with the prolonged 
use of SAP, a meta-analysis of 44 randomised clinical trials (RCTs) confirmed that prolonged 
SAP post-operatively had no benefit in the reduction of surgical-related wound infections as 
opposed to a single dose (WHO, 2016b). Hence there is no need for modifications of the 
72 
 
antibiotic prophylaxis regimen stated in the STG, and certainly no need to prolong prophylaxis 
post-operatively and post-discharge. 
 
Maternal mortality has thus drawn the attention of many and has been regarded as one of the 
most sensitive topics. Much emphasis has been placed on achieving equitable progress to help 
lower the disproportionate burden of poor maternal health in low- and middle-income countries, 
but much is yet to done. Since the MDG5 target of a 75% reduction in maternal mortality was 
not met, there is a need for health systems to act in response to the changing context of women’s 
lives, as urbanisation has not contributed to quality of care for everyone and there is a great need 
to make information more accessible. The risk of a woman dying as a result of pregnancy and 
child birth is more than 100 times greater in sub-Saharan Africa compared to in high-income 
countries (Koblinsky et al., 2016). In high-income countries, there have been successful medical 
interventions that have contributed to much lower maternal and neonatal mortality. However 
doubts have been expressed as to whether the care given was evidence-based, and as a result, 
medical liability costs can be very high (Shaw et al., 2016). The challenges faced by health 
systems regarding poor quality and inaccessible care are constant, despite the improved 
economic or political stability of developing countries. Communities will need to put increased 
pressure on national and regional governments for better harness domestic health spending to 
provide universal health coverage, hence effectively addressing maternal health and achieving 
sustainable improvements in the quality of care (Koblinsky et al., 2016). 
 
5.6 Limitations 
There were several limitations to the present study. The sample size for the qualitative phase 
was small. There was also absence of data in some medical records, such as the exact timing of 
each antibiotic administration, patients BMI values as well as the viral load and CD4 cell count 
of HIV infected patients. There were several cases with incomplete data hence it was not 





5.7 Summary  
This chapter provided an analysis and discussion of the results. It provided an analysis of the 
implications of the identified non-compliance with the NDOH STG, the reasons for such non-
compliance as well as the appropriate remedial actions to be taken on the basis of the results 




CHAPTER VI: CONCLUSIONS AND RECOMMENDATIONS 
6.1 Introduction 
The final chapter highlights the overall conclusions of the study, in addition to providing 
recommendations for further research.  
 
6.2 Conclusions  
Maternal health has demanded the attention of many and has been made a global priority. As a 
result, much focus should be placed on ensuring that pregnant women have access to quality 
care, including quality CS deliveries were warranted. That includes taking all necessary steps to 
avoid the occurrence of post-operative SSI. Part of that effort must include the provision of 
appropriate antibiotic prophylaxis, administered at the right time, in the right dose, by the right 
route of administration and for the right duration. The injudicious use of antibiotics has 
contributed to the emergence of antimicrobial resistance. One form of injudicious use is the 
prolonged administration of prophylactic antibiotics in the absence of an established or 
suspected infection.  
 
This study provides clear evidence that the provision of antibiotic prophylaxis for women 
undergoing CS delivery at Heidelberg Hospital, a district hospital situated in Gauteng was 
irrational. Using MUE methods, the study identified different elements of non-compliance with 
the NDOH standard treatment guidelines. Although the right prophylactic antibiotic (cefazolin) 
was initially prescribed, in all cases, a prolonged course was administered. In those women not 
living with HIV, administration was extended for 3 doses instead of one. However, in those 
women living with HIV, intravenous administration was extended for 3 days, accompanied with 
intravenous metronidazole. All women who had delivered by CS, whether living with HIV or 
not, were also provided with an additional 5 days of oral antibiotics. There was insufficient 
evidence to support the use of therapeutic courses of antibiotics in the women treated at 
Heidelberg Hospital. 
 
Not only would this non-compliance with the STG have contributed to the selective pressure 
that potentially results in increased resistance, it would also have increased the costs incurred 
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and contributed to additional nurse workload on the wards. Although the use of extended 
duration antibiotic resistance was justified by the prescribers on the basis of assumed increased 
risk in those who were presumably immunocompromised, as well as the conditions at the 
hospital which prevented the use of appropriate aseptic techniques, the treatment regimen 
developed and implemented locally is not supported by the existing evidence from the literature. 
Nonetheless, there is mitigating evidence in the form of the draft Maternal Care guidelines, 
which have supported the use of extended dosing in women at presumed higher risk of SSI. The 
study did not provide any justifications for the therapeutic use of antibiotics in patients without 
established or suspected infections post-CS. Instead, the literature summarised for this study has 
provided evidence for the reconsideration of the local hospital protocol. However, there is also a 
need to reconcile the advice provided in the STG with that provided in the Maternal Care 
guidelines. Although the concern for maternal welfare is genuine, and the avoidance of 
preventable complications has been highlighted by the Confidential Enquiries into Maternal 
Mortality, there is still a need to enforce antibiotic stewardship in order to limit the development 
of resistance. Clear support for an unambiguous prophylactic antibiotic regimen in CS should be 




6.3 Recommendations for remedial action 
The following recommendations are offered: 
• the NDOH STG should be made explicit, replacing the “pelvic surgery” entry with an 
unambiguous recommendations for use in women undergoing CS; 
• this STG should support the single-dose regimen of cefazolin IV; 
• clear guidance should be provided, both in the STG and the Maternal Care guidelines, 
on the management of women suspected of having an established infection, and who 
deserve a full therapeutic course of antibiotics; 
• this guidance should be specific about the choice of antibiotic(s), the route(s) of 
administration, and duration; 
• routine monitoring and evaluation systems should be put in place to track compliance 
with the guidelines and identify areas for intervention; and 
• the results of this study should be shared with the Heidelberg Hospital Drug an 
Therapeutics Committee, the Gauteng provincial Pharmacy and Therapeutics 
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Committee, and the relevant antimicrobial stewardship structures, in order to inform the 
development of remedial action. 
 
6.4 Recommendations for further research  
This study has also identified opportunities for further research, including: 
• identifying patients readmitted for sepsis after CS delivery at Heidelberg Hospital, in 
order to identify risk factors that would justify more aggressive initial treatment;  
• investigation of the reasons for resorting to CS at Heidelberg Hospital, in order to avoid 
unnecessary CS and the risks associated with this form of delivery. 
 
6.5 Summary  
The last chapter listed the conclusions drawn from the study, and provided recommendations for 
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APPENDIX 1: INTERVIEW SCHEDULE 
 
1. What has been your experience regarding post-Caesarean section infections in women 
delivered in the Heidelberg Hospital maternity ward? 
______________________________________________________________________ 
2. Have any of your experiences affected your prescribing practices in relation to 
antibiotic prophylaxis in Caesarean sections? 
______________________________________________________________________ 
3. Is there a protocol in place for the administration of antibiotic prophylaxis in patients 
undergoing CS at Heidelberg Hospital? 
______________________________________________________________________ 
4. Are you familiar with the antibiotic prophylaxis recommendations included in the 
National Department of Health Standard Treatment Guidelines (Adult Hospital edition 
2012)? 
______________________________________________________________________ 
5. What antibiotic prophylaxis regimen do you use in CS? 
______________________________________________________________________ 
6. What doses are prescribed and for what duration? 
______________________________________________________________________ 
7. Are there specific reasons why you chose this regimen and this duration? 
______________________________________________________________________ 
8. What doses are used for HIV-positive patients and why? 
______________________________________________________________________ 
9. How would you feel about having to follow a different prophylactic regimen from that 
stated in the NDOH STGs?  
______________________________________________________________________ 
10. What changes or recommendations would you suggest for consideration in the Standard 





































































































































           
           
           
           
           
           
           
           
           
           
           
           
           
           




APPENDIX 4: INTERVIEW SCHEDULE (CLOSED-ENDED) 
1. What has been your experience regarding post-Caesarean section infections in 
women delivered in the Heidelberg Hospital maternity ward?  
 
Common   □                            Rare    □ 
 
2. Have any of your experiences affected your prescribing practices in relation to 
antibiotic prophylaxis in Caesarean sections?  
 
Yes   □            No    □ 
 
3. Is there a protocol in place for the administration of antibiotic prophylaxis in 
patients undergoing CS at Heidelberg Hospital?  
 
Yes   □            No    □   Not Sure    □ 
 
4. Are you familiar with the antibiotic prophylaxis recommendations included in 
the National Department of Health Standard Treatment Guidelines (Adult Hospital 
edition 2012)?  
Yes   □            No    □ 
5. What pre and post antibiotic prophylaxis regimen do you use in CS?  
 
Pre-op:    Cefazolin 1g IVI  
Post-op:  Cefazolin  
Post-discharge: Amoxicillin & Metronidazole 
 
6. What doses are prescribed and for what duration?  
 
Pre-op:   1g                    < 60 minutes before the first incision 
Post-op:  1g    8 hourly IVI  over 24 hour period (3 Doses)  
Post-discharge:  
Amoxicillin  500mg  8hourly P.O over a 5 day period 





7. Are there specific reasons why you chose this regimen and this duration?  
Yes   □          please specify:__________________________                        No    □ 
8. What doses are used for HIV-positive patients and why?  
 
Pre-op:    Cefazolin 1g IVI < 60 minutes before the first incision 
Post-op:  Cefazolin 1g every 8 hours IVI for 3 days (9 doses) 
   Metronidazole 500mg every 8 hours IVI for 3 days (9 doses) 
Post-discharge: Amoxicillin 500mg every 8 hours P.O for 5 days 
              Metronidazole  400mg every 8hours P.O for 5 days 
The CD4 count is not always available and patients are immunocompromised. 
 
9. How would you feel about having to follow a different prophylactic regimen 
from that stated in the NDOH STGs?   
Willing to follow new recommendation provided there is evidence based research     □ 
Not willing since there is no problems with the current regimen       □ 
 
10. Would you suggest any changes or recommendations for consideration in the 
Standard Treatment Guidelines regarding antibiotic prophylaxis in CS?    
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